name: Did you ever not pay your home energy supplier because there wasn't enough money for the bill


name: Did you ever not pay your home energy supplier because there wasn't enough money for the bill:Find:12Mo:^Patient:Ord


name: Did a parent or adult in your home ever hit, beat, kick, or physically hurt you in any way


name: Did a parent or adult in your home ever hit, beat, kick, or physically hurt you in any way:Find:RptPeriod:^Patient:Ord


name: Dead, heavy feeling after starting to exercise


name: Dead, heavy feeling after starting to exercise:Find:6Mo:^Patient:Ord


name: If you do not exercise, is it because exercise makes your symptoms worse


name: If you do not exercise, is it because exercise makes your symptoms worse:Find:6Mo:^Patient:Ord


name: Bothered by Urine Leakage without Urgency or Activity Question


name: Bothered by Urine Leakage with Feeling of Urgency Question


name: Bothered by Strong Feeling of Urgency to Empty Bladder Question


name: Muscles of facial expression:Find:Pt:^Patient:Ord


name: Facial and Oral Movements:-:Pt:^Patient:-


name: Applied Proteogenomics OrganizationaL Learning and Outcomes Network


name: Fear of Embarrassment Restricts Activities Question


name: Urinary Incontinence Impact on Fear of Embarrassment Question


name: Do you stay in a vehicle there:Find:RptPeriod:^Patient:Ord


name: Where were you living or staying before that


name: Where were you living or staying before that:Find:RptPeriod:^Patient:Nom


name: Did you stay in a vehicle there:Find:RptPeriod:^Patient:Ord


name: How often did you feel that you were able to talk to your family about your feelings


name: How often did you feel that you were able to talk to your family about your feelings:Find:Pt:^Patient:Ord


name: How often did you enjoy participating in your community's traditions


name: How often did you enjoy participating in your community's traditions:Find:Pt:^Patient:Ord


name: Metachromatic Leukodystrophy newborn screening panel


name: Metachromatic Leukodystrophy newborn screening panel:-:Pt:Bld.dot:-


name: Drug withdrawal period 1:Time:Pt:^Patient:Nom


name: Previous history of abdominal surgeries:Find:Pt:^Patient:Nom


name: Did you ever use your kitchen stove or oven for heat because there wasn't enough money to pay heating bills:Find:12Mo:^Patient:Ord


name: Did you ever use your kitchen stove or oven for heat because there wasn't enough money to pay heating bills


name: Did you feel that no one in your family loved you or thought you were special


name: Did you feel that no one in your family loved you or thought you were special:Find:RptPeriod:^Patient:Ord


name: Did you have at least one good friend:Find:Pt:^Patient:Ord


name: Did you have beliefs that gave you comfort


name: Did you have beliefs that gave you comfort:Find:Pt:^Patient:Ord


name: Pancreatobiliary endoscopy approach:Find:Pt:^Patient:Nom:Pancreatobiliary Endoscopy


name: I or we worried whether the home energy bill would become overdue before having money to pay it


name: I or we worried whether the home energy bill would become overdue before having money to pay it:Find:12Mo:^Patient:Ord


name: Goal attainment scale GAS baseline:Find:Pt:^Patient:Nom


name: Other substance use status:Find:Pt:^Patient:Nom


name: Mentally tired after the slightest effort


name: Mentally tired after the slightest effort:Find:6Mo:^Patient:Ord


name: Transplant Recipients International Organization


name: Have you ever been unfairly fired or denied a promotion


name: Have you ever been unfairly fired or denied a promotion:Find:Lifetime:^Patient:Ord


name: Do movements disappear in sleep:Find:Pt:^Patient:Nom


name: Do you lease, rent, own, or have a long-term agreement for a place to park or dock:Find:RptPeriod:^Patient:Ord


name: Do you lease, rent, own, or have a long-term agreement for a place to park or dock


name: How often did one or the other of these happen


name: How often did one or the other of these happen:Find:12Mo:^Patient:Ord


name: How often did you feel your family stood by you during difficult times


name: How often did you feel your family stood by you during difficult times:Find:Pt:^Patient:Ord


name: How often were there at least two adults, other than your parents, who took a genuine interest in you:Find:Pt:^Patient:Ord


name: How often were there at least two adults, other than your parents, who took a genuine interest in you


name: I or we couldn't afford to heat or cool our home to desired temperature or use water or appliances to the extent desired


name: I or we couldn't afford to heat or cool our home to desired temperature or use water or appliances to the extent desired:Find:12Mo:^Patient:Ord


name: If you feel worse after activities, how long does this last:Find:6Mo:^Patient:Ord


name: If you feel worse after activities, how long does this last


name: Is it paid for by a charitable organization, government payment, or a voucher:Find:RptPeriod:^Patient:Ord


name: Is it paid for by a charitable organization, government payment, or a voucher


name: Removal of ectopic intraligamentous fetus


name: Bilateral mastectomy with preservation of skin and nipple with synchronous implant


name: Hepatitis C Virus NS5A Protease Inhibitor


name: Emulsification (Physical Chemical Technique)


name: Bilateral mastectomy with preservation of skin and nipple


name: Medical Dictionary for Regulatory Activities Terminology (MedDRA), 28_1


name: Iron binding capacity unsaturated normal


name: Spinal dynamic stabilisation device insertion


name: Cardiac implantable electrical device deactivation


name: Product dispensed by unauthorised provider


name: Product administered in inappropriate setting


name: Product prescribed by unauthorised provider


name: Tissue transglutaminase IgA antibody test


name: Risk of ovarian malignancy algorithm index increased


name: Risk of ovarian malignancy algorithm index decreased


name: Immune effector cell encephalopathy score normal


name: Immune effector cell encephalopathy score abnormal


name: Endoscopic cerebrospinal fluid leak repair


name: Device prescribed for unapproved indication


name: Product prescribed for unapproved indication


name: Pneumococcal urinary antigen test positive


name: Pneumococcal urinary antigen test negative


name: Hospital-only treatment administered in outpatient setting


name: Pre-administration patient monitoring not performed


name: Device-assisted femoral vascular compression therapy


name: Anti-deamidated gliadin peptide IgG antibody


name: Frozen solvent used in drug reconstitution


name: Total anomalous pulmonary venous return sutureless repair


name: Coccidioides antibodies immunodiffusion with reflex to complement fixation


name: Wearable cardioverter defibrillator therapy


name: Facial artery musculomucosal flap surgery


name: CAR transgene level by in-situ hybridisation


name: CAR T-cell clonal expansion quantification in peripheral blood


name: CAR T-cell clonal expansion quantification in periphery


name: CAR T-cell clonal expansion quantification


name: Varicella zoster virus IgM antibody test


name: Varicella zoster virus IgG antibody test


name: Medium fluorescent reticulocyte percentage


name: High fluorescent reticulocyte percentage


name: Haemorrhagic fever virus IgG antibody panel


name: Haemorrhagic fever virus IgM antibody panel


name: Algorithm of drug causality for epidermal necrolysis


name: Transabdominal preperitoneal hernia repair


name: Finger assisted laparoscopic prostatectomy


name: Interdisciplinary multimodal pain therapy


name: CAR T-cell clonal expansion present in peripheral blood


name: CAR T-cell clonal expansion present in periphery


name: Extraperitoneal transvesical adenomectomy of the prostate


name: Chimerism testing after allogeneic therapy


name: AVOBENZONE 2.7 g in 100 g / HOMOSALATE 6 g in 100 g / OCTISALATE 4.5 g in 100 g / OCTOCRYLENE 4.5 g in 100 g TOPICAL LOTION [HAWAIIAN TROPIC]


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL SPRAY [Kids Sunscreen SPF 50]


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTISALATE 50 mg in 1 g / OCTOCRYLENE 80 mg in 1 g TOPICAL STICK [Sun Bum Sunscreen Lip Balm Broad Spectrum SPF 30 Kiwi]


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTOCRYLENE 100 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL STICK [Sun Bum 50 Sunscreen Face Stick]


name: AVOBENZONE 30 mg in 1 g / OCTOCRYLENE 70 mg in 1 g / HOMOSALATE 150 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL SPRAY [Sun Bum Premium Moisturizing Sunscreen Broad Spectrum SPF 50]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL CREAM [Airfit Invisible Sunscreen]


name: HOMOSALATE 100 mg in 1 mL / OCTOCRYLENE 80 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL TOPICAL OINTMENT [Sun Bum Coconut Lip 30 Sunscreen Lip Balm]


name: OCTISALATE 50 g in 1000 g / ZINC OXIDE 110 g in 1000 g TOPICAL LOTION [EltaMD UV Daily Hydration]


name: OCTOCRYLENE 37.5 mg in 1 g / OCTISALATE 50 mg in 1 g / AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g TOPICAL SPRAY [Premium Moisturizing Sunscreen Broad Spectrum SPF 30]


name: ZINC OXIDE 19 g in 100 mL TOPICAL CREAM [Tallow Sunscreen SPF 30]


name: ZINC OXIDE 200 mg in 1 mL TOPICAL LOTION [Baby Bum Mineral 50 Sunscreen]


name: ZINC OXIDE 230 mg in 1 g TOPICAL STICK [Sun Bum Signature High Performance Mineral Sunscreen Face Stick 30]


name: DIMETHICONE 5 g in 100 g TOPICAL CREAM [Awaken Moisturizing Cream]


name: SODIUM CHLORIDE 100 g in 100 mL TOPICAL LIQUID [NATURAL LIQUIDMINERALSPRAY]


name: SODIUM CHLORIDE 100 g in 100 mL TOPICAL LIQUID [NATURAL LIQUIDMINERAL]


name: SULFAQUINOXALINE SODIUM 1 kg in 1 kg POWDER


name: TICARCILLIN DISODIUM 968 mg in 1 g / CLAVULANATE POTASSIUM 32 mg in 1 g NOT APPLICABLE POWDER


name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Duette Tinted]


name: ZINC OXIDE 20 g in 100 mL TOPICAL LOTION [Dermatone Mineral SPF 30]


name: ACETYL HEXAPEPTIDE-8 AMIDE 0.006 mg in 30 mg / ROSE OIL 0.006 mg in 30 mg TOPICAL PATCH [XIMONTH GLP-1 Patches]


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 15 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 8 g in 100 g TOPICAL SPRAY [Broad Spectrum SPF 15 sunscreen]


name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 7.34 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL LOTION [ILLUSION LUMINOUS GLOW FOUNDATION]


name: ZINC OXIDE 19 g in 100 g TOPICAL CREAM [Vigority Tallow Sunscreen SPF30]


name: ZINC OXIDE 25 g in 100 mL TOPICAL CREAM [Kids Tallow Sunscreen SPF50]


name: SULFAMERAZINE SODIUM 1 kg in 1 kg POWDER


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 15 g in 100 g / OCTISALATE 10 g in 100 g TOPICAL SPRAY [Broad Spectrum SPF 50 sunscreen]


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 15 g in 100 g / OCTISALATE 7.5 g in 100 g TOPICAL SPRAY [Broad Spectrum SPF 30 sunscreen]


name: ZINC OXIDE 138 mg in 1 g TOPICAL STICK [Sun Bum 50 Mineral Sunscreen Face Stick]


name: ZINC OXIDE 15 g in 100 mL TOPICAL SPRAY [SPF 30 Mineral Whipped Creams Shimmer]


name: ZINC OXIDE 192 mg in 1 g TOPICAL STICK [Baby Bum Mineral 50 Mineral Sunscreen Face Stick]


name: MOLNUPIRAVIR 1 g in 1 g NOT APPLICABLE POWDER


name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 19 g in 100 g TOPICAL CREAM [Old Spice Sweat Defense Swagger]


name: HOMOSALATE 65 mg in 1 mL / AVOBENZONE 28 mg in 1 mL / OCTOCRYLENE 80 mg in 1 mL / OCTISALATE 45 mg in 1 mL TOPICAL GEL [Abib Airy clear sunscreen gel Smoothing tube]


name: LACTIC ACID 1.5 U in 100 U / POLYAMINOPROPYL BIGUANIDE 0.2 U in 100 U TOPICAL CLOTH


name: Clotrimazole antifungal treatment kit KIT


name: ALUMINUM CHLOROHYDRATE 16 g in 100 g TOPICAL CREAM [Odorono Antiperspirant and Deodorant Roll-on Original]


name: ALUMINUM CHLOROHYDRATE 20 g in 100 mL TOPICAL LIQUID [Confielle Antiperspirant and Deodorant Roll-on Original]


name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 80 mg in 1 mL / HOMOSALATE 100 mg in 1 mL TOPICAL OINTMENT [Sun Bum Coconut Lip 30 Tinted Sunscreen Lip Balm - Bonfire]


name: ENSULIZOLE 0.02 g in 1 g / HOMOSALATE 0.05 g in 1 g / OCTINOXATE 0.04995 g in 1 g / TITANIUM DIOXIDE 0.106015 g in 1 g TOPICAL LOTION [PHOFAY Matte Sunscreen Liquid Foundation SPF 30 6]


name: ENSULIZOLE 0.02 g in 1 g / OCTINOXATE 0.04995 g in 1 g / TITANIUM DIOXIDE 0.11765 g in 1 g / HOMOSALATE 0.05 g in 1 g TOPICAL LOTION [PHOFAY Matte Sunscreen Liquid Foundation SPF 30 4]


name: ENSULIZOLE 0.02 g in 1 g / OCTINOXATE 0.04995 g in 1 g / TITANIUM DIOXIDE 0.13 g in 1 g / HOMOSALATE 0.05 g in 1 g TOPICAL LOTION [PHOFAY Matte Sunscreen Liquid Foundation SPF 30 2]


name: HOMOSALATE 0.05 g in 1 g / ENSULIZOLE 0.02 g in 1 g / TITANIUM DIOXIDE 0.10725 g in 1 g / OCTINOXATE 0.04995 g in 1 g TOPICAL LOTION [PHOFAY Matte Sunscreen Liquid Foundation SPF 30 5]


name: HOMOSALATE 0.05 g in 1 g / ENSULIZOLE 0.02 g in 1 g / TITANIUM DIOXIDE 0.119405 g in 1 g / OCTINOXATE 0.04995 g in 1 g TOPICAL LOTION [PHOFAY Matte Sunscreen Liquid Foundation SPF 30 3]


name: HOMOSALATE 100 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 80 mg in 1 mL TOPICAL OINTMENT [Sun Bum Coconut Lip 30 Tinted Sunscreen Lip Balm - Sunset Cove]


name: HOMOSALATE 80 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL TOPICAL LIPSTICK [LALICIOUS HYDRATING BUTTER GLOSS SPF 30 BERRY BOMB]


name: OCTINOXATE 60 mg in 1 mL / OCTISALATE 20 mg in 1 mL / TITANIUM DIOXIDE 15.6 mg in 1 mL / ZINC OXIDE 19.2 mg in 1 mL TOPICAL CREAM [ERBORIAN CC CREME Color Correcting SPF 25 FAIR]


name: OCTINOXATE 60 mg in 1 mL / OCTISALATE 20 mg in 1 mL / TITANIUM DIOXIDE 23.4 mg in 1 mL / ZINC OXIDE 38.4 mg in 1 mL TOPICAL CREAM [ERBORIAN CC CREME Color Correcting SPF 25 BRONZE]


name: OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / HOMOSALATE 135 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [Neutrogena Hydro Boost Hyaluronic Acid Moisturizer Broad Spectrum SPF 50]


name: OCTOCRYLENE 9 g in 100 mL / ETHYLHEXYL SALICYLATE 4.5 g in 100 mL / BUTYL METHOXYDIBENZOYLMETHANE 2.7 g in 100 mL / HOMOSALATE 13.6 g in 100 mL TOPICAL CREAM [SKIN1004 MADAGASCAR CENTELLA HYALU-CICA WATER-FIT SUN SERUM UV]


name: TITANIUM DIOXIDE 19.4 mg in 1 mL / ZINC OXIDE 9.7 mg in 1 mL TOPICAL LOTION [Wander Beauty Pack Up and Glow Priming]


name: TITANIUM DIOXIDE 19.4 mg in 1 mL / ZINC OXIDE 9.7 mg in 1 mL TOPICAL LOTION [Woro Beauty SPFortless]


name: ZINC OXIDE 206 mg in 1 g TOPICAL SPRAY [Ocean Potion Suncare Mineral 50 Essential Scent of Sunshine Zinc Oxide Continuous Sunscreen]


name: ZINC OXIDE 207 mg in 1 mL / TITANIUM DIOXIDE 38 mg in 1 mL TOPICAL CREAM [UV SOLUTIONS BRIGHTENING TINTED BROAD SPECTRUM SPF 50 SUNSCREEN NIACINAMIDE ANTIOXIDANTS]


name: ALUMINUM SESQUICHLOROHYDRATE 9.6 g in 100 g TOPICAL STICK [Axe]


name: CAPRYLIC/CAPRIC TRIGLYCERIDE 3 mg in 120 g / GLYCERIN 4 mg in 120 g CUTANEOUS CREAM


name: GLYCERIN 4 mg in 120 g / POLYSORBATE 60 3 mg in 120 g CUTANEOUS CREAM


name: {1 (dextromethorphan hydrobromide 1 MG/ML / guaifenesin 10 MG/ML Oral Solution) / 1 (dextromethorphan hydrobromide 1.5 MG/ML / doxylamine succinate 0.625 MG/ML Oral Solution) } Pack


name: Ace Night Wrist Sleep Support Adjustable


name: Polident 3 Minute Antibacterial Dental Tablet


name: Polident Smoker Antibacterial Dental Tablets


name: Secret Antiperspirant Powder Fresh Aerosol


name: True Metrix Blood Glucose Monitoring System


name: TITANIUM DIOXIDE 10.4 g in 100 g TOPICAL CREAM [toty Ilumina CC Creamy Compact 1C]


name: DRESSING,QUIKCLOT EMS HEMOSTATIC 4IN X 4IN


name: CATHETER,FOLEY 2-WAY 24FR 30ML CARDINAL HEALTH #681424


name: TRACHEAL SUCTION SET SZ 8 SMITH #101875080


name: LIQUID HOPE PEPTIDE BERRY MEDLEY FORMULA


name: BANDAGE TUBULAR ELASTIC 8 1/4IN X 11YD SAG13118


name: TRACHEAL SUCTION SET 14FR BALLARD #22705


name: HEAT & MOISTURE EXCHANGER,DYNAREX #30303


name: CATHETER,FOLEY COUDE 22FR 30ML BARD#0100L-22


name: CareSens S Fit BT Blood Glucose Monitoring System


name: CareSens S Fit Blood Glucose Monitoring System


name: POLIDENT 3 Minute Antibacterial Dental Appliance Cleanser Tablet (Mint Fresh)


name: POLIDENT Overnight Whitening Antibacterial Dental Appliance Cleanser Tablet


name: POLIDENT Smokers Antibacterial Dental Appliance Cleanser Tablet


name: POLIGRIP Power Max Ultimate All in 1 Denture Adhesive Cream


name: SUN BURNT After-Sun Daily Recovery Body Wash


name: Benefiber Prebiotic + Supergreens Powder for Solution (Strawberry Dragon Fruit)


name: Benefiber Prebiotic + Supergreens Powder for Solution (Watermelon Lemonade)


name: blade lancet, safety 1.5 mm X 1.2 mm MISCELL EACH


name: blade lancet, safety 1.5 mm X 1.6 mm MISCELL EACH


name: compression stocking,knee high,regular length,2x-large circ MISCELL EACH


name: compression stocking,knee high,regular length,3x-large circ MISCELL EACH


name: emollient combination no.125 TOPICAL CREAM (GRAM)


name: infant formula sulfite oxidase deficiency with iron/dha/ara 13.5 gram-466 kcal/100 gram ORAL POWDER (GRAM)


name: nut.tx.impaired digest fxn/inulin/fructooligosaccharides 0.0756 gram-1.2 kcal/mL ORAL LIQUID (ML)


name: compress. stocking,knee high,regular length, 2x-lg


name: compress. stocking,knee high,regular length, 3x-lg


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTISALATE 50 mg in 1 g / OCTOCRYLENE 80 mg in 1 g TOPICAL STICK [Sun Bum Day Tripper - SPF 30 Sunscreen Lip Balm (Coconut) 0.15 OZ]


name: HOMOSALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / OCTISALATE 30 mg in 1 mL TOPICAL LOTION [Sun Bum Day Tripper - SPF 30 Moisturizing Sunscreen 3 OZ]


name: OCTINOXATE 7.5 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 5 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL STICK [Basin Sugar Plum SPF 15 Broad Spectrum Sunscreen Lip Balm]


name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 4 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL STICK [Basin Mint SPF 30 Broad Spectrum Sunscreen Lip Balm SPF 30]


name: OCTISALATE 50 mg in 1 g / OCTOCRYLENE 100 mg in 1 g / AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g TOPICAL STICK [Sun Bum Premium Sunscreen Face Stick Broad Spectrum SPF 30 Sunscreen - Pegged]


name: OXYBENZONE 3 g in 100 g / OCTINOXATE 7.5 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL LOTION [Purpose Dual Treatment SPF 10]


name: ZINC OXIDE 138 mg in 1 g TOPICAL STICK [Sun Bum Road Tripper Mineral - Mineral Sunscreen Face Stick Broad Spectrum SPF 50]


name: ZINC OXIDE 147 mg in 1 mL TOPICAL LOTION [Sun Bum Road Tripper Mineral - Mineral Sunscreen Broad Spectrum SPF 30]


name: AVOBENZONE 15 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 40 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL CREAM [Curology Daily Moisturizing Sunscreen SPF 30]


name: ZINC OXIDE 200 mg in 1 mL TOPICAL EMULSION [Damastique SPF Active Serum SPF 36]


name: ZINC OXIDE 80 mg in 1 g TOPICAL STICK [Sun Bum Road Tripper Mineral - Mineral Lip Balm Broad Spectrum SPF 30]


name: OCTINOXATE 7.4 g in 100 g / HOMOSALATE 6.2 g in 100 g / OCTISALATE 5.0 g in 100 g / OXYBENZONE 3.1 g in 100 g / AVOBENZONE 1.5 g in 100 g TOPICAL CREAM [Introstem PrismaStem Face Shield Cream]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 159 mg in 1 g TOPICAL STICK [Speed Stick Clean Antiperspirant Deodorant]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 159 mg in 1 g TOPICAL STICK [Speed Stick Irish Spring Original]


name: ZINC OXIDE 15.7 g in 100 mL TOPICAL LOTION [MAYDAY Everyday Sunscreen SPF 30]


name: ALCOHOL 72.6 g in 100 mL / SODIUM PROPIONATE 0.5 g in 100 mL TOPICAL LIQUID [Animal Science Product ANIMEND]


name: {1 (acetaminophen 325 MG / dextromethorphan hydrobromide 10 MG / guaifenesin 200 MG / pseudoephedrine hydrochloride 30 MG Oral Capsule) / 1 (acetaminophen 500 MG / dextromethorphan hydrobromide 15 MG / doxylamine succinate 6.25 MG / pseudoephedrine hydrochloride 30 MG Oral Capsule) } Pack


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTOCRYLENE 40 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL SPRAY [Ocean Potion Suncare 50 Continuous Sunscreen Scent of Sunshine]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL TOPICAL CREAM [CLARINS Extra Firming Sunscreen SPF 15]


name: ZINC OXIDE 206 mg in 1 mL TOPICAL LOTION [Ocean Potion Suncare Mineral 30 Essential Scent of Sunshine Zinc Oxide Sunscreen]


name: ARNICA MONTANA 7 g in 100 g TOPICAL CREAM [SupreH Arnica Bruise Cream]


name: Treatonic Toenail Fungus Treatment Kit KIT


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTOCRYLENE 20 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL SPRAY [Ocean Potion Suncare 30 Continuous Sunscreen Scent of Sunshine]


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 150 mg in 1 g / OCTOCRYLENE 100 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL SPRAY [Ocean Potion Suncare 70 Continuous Sunscreen Scent of Sunshine]


name: OCTISALATE 30 mg in 1 mL / AVOBENZONE 40 mg in 1 mL / HOMOSALATE 30 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL TOPICAL CREAM [Sunglaze Body Gel Cream Sunscreen SPF50]


name: BENZOCAINE 7.5 g in 100 mL TOPICAL SPRAY [LubeLife Climax Control Delay]


name: ZINC OXIDE 150 mg in 1 mL TOPICAL CREAM [Good Weather Skin The One Daily Sun Warm Glow SPF 30]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 158 mg in 1 g TOPICAL STICK [Speed stick Power Ultimate Sport]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 161 mg in 1 g TOPICAL STICK [Speed Stick Unscented Antiperspirant Deodorant]


name: ENSULIZOLE 20 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTINOXATE 49.95 mg in 1 mL / TITANIUM DIOXIDE 124.475 mg in 1 mL TOPICAL LIQUID [PHOFAY Matte Sunscreen Liquid Foundation SPF 30, 1]


name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 4 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL STICK [Basin Sun Stick SPF 30]


name: ZINC OXIDE 23 mg in 1 g TOPICAL LOTION [Hello Bello Kids Mineral Sunscreen]


name: HONEY 0.01 mg in 50 mg TOPICAL LIQUID [XIMONTH Bee Honey Eye Drops]


name: ALUMINUM CHLOROHYDRATE 15 g in 100 g TOPICAL SPRAY [87066-5912]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 160 mg in 1 g TOPICAL STICK [Ladies Speed Stick Teen Spirit Fresh Zing]


name: ZINC OXIDE 200 mg in 1 g TOPICAL CREAM [Mineral Based Facial Sunscreen]


name: ZINC OXIDE 25 g in 100 g TOPICAL CREAM [Sheer Guard Natural Mineral Sunscreen Broad Spectrum SPF 50]


name: Zinc Oxide 67.3 mg in 1 mL / Octinoxate 57.5 mg in 1 mL / OXYBENZONE 45 mg in 1 mL / Octisalate 38.3 mg in 1 mL TOPICAL LOTION [Beach Club Mineral Sunscreen]


name: TITANIUM DIOXIDE 4 g in 100 g / ETHYLHEXYL METHOXYCINNAMATE 7.5 g in 100 g TOPICAL LOTION [sunscreen]


name: OCTINOXATE 7.5 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 5 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL STICK [Basin Pina Colada SPF 15 Broad Spectrum Sunscreen Lip Balm]


name: OCTOCRYLENE 4.35 g in 50 mL / AVOBENZONE 1.5 g in 50 mL / OCTISALATE 2.5 g in 50 mL / HOMOSALATE 5 g in 50 mL TOPICAL CREAM [TOSOWOONG Rice Glow SunScreen]


name: BENZOCAINE 7.5 g in 100 mL TOPICAL SPRAY [JO Prolonger with Benzocaine]


name: ZINC OXIDE 18 g in 100 mL TOPICAL LOTION [naked TURTLE 30]


name: LASALOCID SODIUM 50 kg in 50 kg NOT APPLICABLE POWDER


name: LIDOCAINE HYDROCHLORIDE 10 g in 10 g TOPICAL SPRAY [JO for Him Prolonger with Lidocaine]


name: MELISSA OFFICINALIS LEAF 7 g in 531.1 g / EUCALYPTUS OIL 2.3 g in 531.1 g / MELALEUCA ALTERNIFOLIA (TEA TREE) LEAF OIL 2.2 g in 531.1 g TOPICAL SALVE [Sea Jewels Lemon Balm Full Body Salve]


name: PAROXETINE HYDROCHLORIDE 1 g in 1 g NOT APPLICABLE POWDER


name: ZINC OXIDE 25 kg in 100 kg TOPICAL CREAM [Sun Zapper - Acne Pure Zinc Sunscreen SPF50]


name: AVOBENZONE 30 mg in 1 g / OCTOCRYLENE 40 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL SPRAY [Klein Tools Sunscreen SPF 50]


name: HOMOSALATE 100 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL LOTION [Klein Tools Sunscreen SPF 50]


name: ESTRIOL 0.2 g in 100 g TOPICAL CREAM [MYEVER]


name: ZINC OXIDE 25 kg in 100 kg TOPICAL CREAM [Sun Zapper - Baby pure zinc sunscreen SPF30]


name: ZINC OXIDE 250 mg in 1 g TOPICAL CREAM [Sun and Honey Tallow Sunscreen SPF 30]


name: ZINC OXIDE 67.3 mg in 1 mL / OCTINOXATE 57.5 mg in 1 mL / OXYBENZONE 45 mg in 1 mL / OCTISALATE 38.3 mg in 1 mL TOPICAL LOTION [I.C. Industrial Sunscreen]


name: ALUMINUM CHLOROHYDRATE 15 g in 100 mL TOPICAL OINTMENT [NYU Langone Health Deodorant]


name: ROSEMARY OIL 750 mg in 25 mL CUTANEOUS LIQUID [HAIR GROWTH SERUM ROLL-ON]


name: ZINC OXIDE 175 mg in 1 mL TOPICAL CREAM [SkinSuit TM 3 in 1 Moisturizer SPF 50]


name: ALUMINUM CHLOROHYDRATE 20 g in 100 mL TOPICAL LIQUID [Louis Philippe Antiperspirant and Deodorant Roll-on Original]


name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [DMK Ultrascreen Mineral Sunscreen]


name: MELALEUCA ALTERNIFOLIA FLOWERING TOP 0.006 mg in 30 mg / HAMAMELIS VIRGINIANA (WITCH HAZEL) LEAF WATER 0.006 mg in 30 mg TOPICAL LIQUID [EELHOE Skin Advanced Mole Remove Serum]


name: THYMUS VULGARIS (THYME) FLOWER/LEAF OIL 0.006 mg in 30 mg / COMMIPHORA MYRRHA RESIN 0.006 mg in 30 mg TOPICAL LIQUID [SOUTH MOON Ingrown Toenail Drops]


name: ZINC OXIDE 25 kg in 100 kg TOPICAL CREAM [Sun Zapper - Anti-ageing pure zinc sunscreen SPF30]


name: ZINC OXIDE 5 g in 100 mL / TITANIUM DIOXIDE 6 g in 100 mL TOPICAL LOTION [CVS SPF 50 Face Sunscreen]


name: ZINC OXIDE 0.65 kg in 100 kg TOPICAL LOTION [EquateDaytimeFaceLotion]


name: {1 (4 ML docetaxel 20 MG/ML Injection) / 1 (50 ML albumin human-kjda 250 MG/ML Injection) } Pack


name: {2 (4 ML docetaxel 20 MG/ML Injection) / 1 (50 ML albumin human-kjda 250 MG/ML Injection) } Pack


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 105 mg in 1 g TOPICAL STICK [Speed Stick Power Fresh Power Fresh]


name: OCTISALATE 5 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LIQUID [CVS SPF 60 Face Sunscreen]


name: OCTOCRYLENE 3 mg in 100 g / METHYLENE BIS-BENZOTRIAZOLYL TETRAMETHYLBUTYLPHENOL 0.75 mg in 100 g / ETHYLHEXYL METHOXYCINNAMATE 5.9958 mg in 100 g / 4-METHYLBENZYLIDENE CAMPHOR 2 mg in 100 g / PHENYLBENZIMIDAZOLE SULFONIC ACID 1 mg in 100 g / HONEY 0.001 mg in 100 g / SACCHAROMYCES LYSATE 0.00885 mg in 100 g / HYDROLYSED MARINE COLLAGEN (ENZYMATIC; 2000 MW) 0.01 mg in 100 g TOPICAL CREAM [XUEYI SKIN CARE SUNSCREEN]


name: ZINC OXIDE 160 mg in 1 g TOPICAL CREAM [Mineral Sunscreen]


name: ZINC OXIDE 200 mg in 1 g TOPICAL CREAM [Bella Blu Skin Care Non Tinted Sunscreen]


name: ZINC OXIDE 200 mg in 1 g TOPICAL CREAM [Bella Blue Skin Care Tinted Sunscreen]


name: POLIHEXANIDE HYDROCHLORIDE 0.15 U in 100 U TOPICAL CLOTH


name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [Sun Bum Daily Glow Tinted Sunscreen Moisturizer Broad Spectrum SPF 30]


name: HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 8 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [Oh My Bod Light Sunscreen Broad Spectrum SPF 50]


name: OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / HOMOSALATE 90 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [Sun Bum Daily Face Liquid Sunscreen Moisturizer Broad Spectrum SPF 50]


name: OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL / HOMOSALATE 80 mg in 1 mL TOPICAL LOTION [Sun Bum Daily Body]


name: OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / HOMOSALATE 90 mg in 1 mL TOPICAL GEL [Sun Bum Daily Gel Gel Sunscreen Moisturizer Broad Spectrum SPF 50]


name: OCTOCRYLENE 8 g in 100 mL / AVOBENZONE 3 g in 100 mL / OCTISALATE 5 g in 100 mL / HOMOSALATE 10 g in 100 mL TOPICAL CREAM [Daily Body Moisturizer Sunscreen Broad Spectrum SPF 50]


name: OCTOCRYLENE 8 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL CREAM [Protect and Hydrate Radiance Sunscreen Broad Spectrum SPF 50]


name: TITANIUM DIOXIDE 8 g in 100 g CUTANEOUS CREAM


name: ZINC OXIDE 120 mg in 1 mL TOPICAL CREAM [Bubble Solar Mate Daily Mineral Sunscreen SPF 40]


name: ZINC OXIDE 138 mg in 1 g TOPICAL STICK [Mtn. Bum by Sun Bum and Mcfetridge Mineral Sunscreen Face Stick SPF 50]


name: ZINC OXIDE 170 mg in 1 mL TOPICAL CREAM [Radiant Shield Tinted Mineral Sunscreen SPF 40]


name: ZINC OXIDE 25 g in 100 g CUTANEOUS CREAM [Face and Body Sunscreen]


name: Direct Glomerular Filtration Rate from Beta-2 Microglobulin Adjusted for Standard BSA Measurement


name: Allergen Skin Response Index Measurement


name: Allergen Skin Response Intensity Measurement


name: Antigenic Skin Flare Longest Diameter Measurement


name: Antigenic Skin Flare Mean Diameter Measurement


name: Clinical or Research Assessment Classification


name: Application Program Freezes or Fails to Launch


name: Appropriate Investigation Findings Term/Code Not Available


name: Appropriate Investigation Conclusion Term/Code Not Available


name: Cause Traced to Missing or Inadequate Safety Measures


name: Premature Indicator Activation Identified


name: Device Problem Related to Variant/Mutant


name: Blood and Lymphatic System Disorders, CTCAE_5


name: General Disorders and Administration Site Conditions, CTCAE_5


name: Injury, Poisoning and Procedural Complications, CTCAE_5


name: Metabolism and Nutrition Disorders, CTCAE_5


name: Musculoskeletal and Connective Tissue Disorders, CTCAE_5


name: Pregnancy, Puerperium and Perinatal Conditions, CTCAE_5


name: Reproductive System and Breast Disorders, CTCAE_5


name: Respiratory, Thoracic and Mediastinal Disorders, CTCAE_5


name: Skin and Subcutaneous Tissue Disorders, CTCAE_5


name: Congenital, Familial and Genetic Disorders, CTCAE_5


name: Surgical and Medical Procedures, CTCAE_5


name: Insufficient Device Problem Information for Adverse Event


name: Insufficient Component Information to Classify Device


name: Autosomal Dominant Pathogenic Germline Variant


name: Measurable Residual Disease Less than 0.01 Percent


name: Measurable Residual Disease 0.01 Percent or Greater


name: NIH Clinical Center, Center for Cellular Engineering


name: Measurable Residual Disease Less than 1 Percent


name: Abnormal Antenatal Hematology Test Result


name: Abnormal Finding on Diagnostic Abdominal Imaging


name: Personal History of Digestive System Cancer


name: Clinical Molecular Genetic Testing Variant Interpretation Guidelines


name: American College of Medical Genetics and Genomics Variant Interpretation Guidelines Prior to 2015


name: Association for Molecular Pathology, American College of Medical Genetics and Genomics, and College of American Pathologists 2015 Variant Interpretation Guidelines


name: Association for Molecular Pathology, American College of Medical Genetics and Genomics, American Society of Clinical Oncology, and College of American Pathologists 2017 Somatic Variant Interpretation Guidelines


name: Clinical Genome Resource, Cancer Genomics Consortium, and Variant Interpretation for Cancer Consortium 2022 Variant Interpretation Guidelines


name: Clinical Genome Resource 2024 Risk Allelic Variant Evidence Guidelines


name: CDISC DDF Alias Code Attribute Terminology


name: CDISC DDF Comment Annotation Attribute Terminology


name: CDISC DDF Narrative Content Item Attribute Terminology


name: CDISC DDF Study Definition Document Attribute Terminology


name: CDISC DDF Study Definition Document Version Attribute Terminology


name: CDISC DDF Abbreviation Attribute Terminology


name: CDISC DDF Reference Identifier Attribute Terminology


name: CDISC DDF Identifier Attribute Terminology


name: CDISC DDF Administrable Product Attribute Terminology


name: CDISC DDF Administrable Product Identifier Attribute Terminology


name: CDISC DDF Administrable Product Property Attribute Terminology


name: CDISC DDF Substance Attribute Terminology


name: CDISC DDF Strength Attribute Terminology


name: CDISC DDF Ingredient Attribute Terminology


name: CDISC DDF Assigned Person Attribute Terminology


name: CDISC DDF Study Role Attribute Terminology


name: CDISC DDF Study Change Attribute Terminology


name: CDISC DDF Document Content Reference Attribute Terminology


name: CDISC DDF Study Amendment Impact Attribute Terminology


name: CDISC DDF Medical Device Attribute Terminology


name: CDISC DDF Medical Device Identifier Attribute Terminology


name: CDISC DDF Product Organization Role Attribute Terminology


name: CDISC DDF Interventional Study Design Attribute Terminology


name: CDISC DDF Observational Study Design Attribute Terminology


name: CDISC DDF Biospecimen Retention Attribute Terminology


name: CDISC DDF Eligibility Criterion Item Attribute Terminology


name: CDISC DDF Study Definition Document Type Value Set Terminology


name: CDISC DDF Reference Identifier Type Value Set Terminology


name: CDISC DDF Administrable Product Property Type Value Set Terminology


name: CDISC DDF Study Role Code Value Set Terminology


name: CDISC DDF Study Amendment Impact Type Value Set Terminology


name: CDISC DDF Medical Device Sourcing Value Set Terminology


name: CDISC DDF Administrable Product Sourcing Value Set Terminology


name: CDISC DDF Medical Device Identifier Type Value Set Terminology


name: CDISC DDF Product Organization Role Code Value Set Terminology


name: CDISC DDF Observational Study Design Subtype Value Set Terminology


name: Study Design Population Planned Completion Number Range


name: Study Design Population Planned Enrollment Number Range


name: Narrative Content Section Title Display Indicator


name: Narrative Content Section Number Display Indicator


name: Study Cohort Planned Enrollment Number Range


name: Population Definition Planned Completion Number Range


name: Population Definition Planned Enrollment Number Range


name: Administrable Product Definition Description


name: Administrable Product Pharmacologic Class


name: Administrable Product Sourcing Indicator


name: Administrable Product Designation Indicator


name: Document Content Reference Section Number


name: Document Content Reference Section Title


name: Interventional Study Design Characteristic


name: Interventional Study Design Therapeutic Areas


name: Observational Study Design Characteristics


name: Observational Study Design Therapeutic Area


name: Multicenter Randomized Controlled Clinical Trial


name: Anti-nectin-4 Antibody-drug Conjugate IPH4502


name: How Much Urine Leaks Interfere with Life Question


name: How Often Have Leaked Urine When Feel Sudden Need Question


name: How Often Have Leaked Urine While Laughing, Sneezing, or Coughing Question


name: How Often Have Leaked Urine When Doing Activities Question


name: How Often Have Bladder Pain or Discomfort While Filling Question


name: How Often Delay Before Urination Question


name: How Often Slow or Weak Urine Flow Question


name: How Often Dribble Urine After Fixing Clothes Question


name: Urinary Frequency During Waking Hours Question


name: How Bothered by Urinary Symptoms Question


name: Anti-CD25 Antibody-drug Conjugate PF-08046032


name: Anti-DLL3 Antibody-drug Conjugate FZ-AD005


name: Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate IBI3005


name: Anti-HER2 Antibody-drug Conjugate FDA022-BB05


name: Anti-TROP2 Antibody-drug Conjugate ESG401


name: Never Lose Gas From Rectum Beyond Control


name: No Difficulty Completely Emptying Bowels


name: Leak Urine When Physically Active or Exercising


name: Blasts 1 Percent or Less of Peripheral Blood White Cells


name: Neoplastic Plasma Cells 1 Percent or Less of Peripheral Blood White Cells


name: Blood Pressure Results with Results for Children Optional


name: Anti-IL-18BP Monoclonal Antibody GS-0321


name: Platelet Count Greater than or Equal to 100000


name: Anti-PD-1 Antibody/Anti-CTLA-4 Antibody/CD40 Agonist/TLR9 Agonist SV-102


name: Aluminum Acetate/Strontium Chloride Hexahydrate Topical Hydrogel


name: WHO Classification of Tumors of the Central Nervous System 2021


name: Anti-PD-1 Antibody/IL-18 Variant Immunocytokine BPT567


name: Actinium Ac 225 GPC3-targeted Peptide RYZ801


name: Quantitative Lipid/Lipoprotein Particle Nuclear Magnetic Resonance Spectroscopy


name: CDISC DDF Person Name Attribute Terminology


name: CDISC DDF Duration Attribute Terminology


name: Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986449


name: Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301


name: Cancer Genome Characterization Initiative


name: Medical Image De-identification Benchmark


name: E. coli-targeting Genetically Modified Bacteriophage SNIPR001


name: Molecular Profiling to Predict Response to Treatment


name: PDX Development and Trial Centers Research Network


name: Quantitative Imaging Biomarkers Alliance


name: Reference Image Database to Evaluate Therapy Response


name: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology


name: Fear of Cancer Recurrence Inventory - Short Form


name: West Coast Prostate Cancer Dream Team Project


name: Evelyn H. Lauder Founder's Fund for Metastatic Breast Cancer Research


name: Proteogenomic Translational Research Center


name: ICH M11 Trial Phase Value Set Terminology


name: ICH M11 Amendment Scope Value Set Terminology


name: ICH M11 Units of Measure Value Set Terminology


name: ICH M11 Trial Site Distribution Value Set Terminology


name: ICH M11 Trial Site Geographic Scope Value Set Terminology


name: ICH M11 Trial Blind Schema Value Set Terminology


name: Loose Skeletal Fragments in Synovial Joint


name: Unspecified Skin and Subcutaneous Tissue Problem


name: Testing of Patient Sample Using Manufacturer's Device


name: Testing of Reference Material Using Manufacturer's Device


name: Device Data not Available for Manufacturer Analysis


name: Single Protein Encapsulated Doxorubicin SPEDOX-6


name: Anti-ROR1 Antibody-drug Conjugate IM-1021


name: Clinical or Research Assessment Category


name: Anti-ADAM9/Exatecan Antibody-drug Conjugate MGC028


name: Abdominal and Retroperitoneal Biopsy Procedure


name: Molecular International Prognostic Scoring System for Myelodysplastic Syndromes


name: Body Mass Index Percentile by Age and Sex


name: Exhaled Carbon Monoxide Concentration Less than or Equal to 4 ppm


name: Primary Site of Origin in the Gastrointestinal Tract Unknown


name: Not Sexually Active Because No Partner Question


name: Not Sexually Active Because No Interest Question


name: Not Sexually Active Because of Bladder Problems Question


name: Not Sexually Active Because of Other Health Problems Question


name: Not Sexually Active Because of Pain Question


name: Not Sexually Active Because of Fear of Incontinence or Prolapse Question


name: Feel Sexually Inferior Due to Incontinence and/or Prolapse Question


name: Feel Angry About Impact of Incontinence and/or Prolapse on Sex Life Question


name: How Bothered by Not Being Sexually Active Question


name: How Often Aroused During Sexual Activity Question


name: How Often Fulfilled by Sexual Activity Question


name: How Often Leak Urine or Stool During Sexual Activity Question


name: How Intense are Current Orgasms Question


name: How Often Feel Pain During Sexual Activity Question


name: Partner's Problem Limits Sexual Activity Question


name: Partner's Impact on Sexual Activity Question


name: How Often Want More Sexual Activity Question


name: Feel Embarassed About Sex Life Due to Incontinence Question


name: ICH M11 Protocol Section Name and Number Value Set Terminology


name: ICH M11 Sponsor Approval Date Value Set Terminology


name: ICH M11 Amendment Details Statement Value Set Terminology


name: ICH M11 Amendment Scope Enrollment Description Value Set Terminology


name: ICH M11 Reason for Amendment Value Set Terminology


name: ICH M11 Intervention Model Value Set Terminology


name: ICH M11 Population Type Value Set Terminology


name: ICH M11 Control Type Value Set Terminology


name: ICH M11 Trial Intervention Assignment Method Value Set Terminology


name: ICH M11 Trial Blinding Role Value Set Terminology


name: ICH M11 Independent Committee Name Value Set Terminology


name: ICH M11 Trial Arm Type Value Set Terminology


name: ICH M11 Intervention Type Value Set Terminology


name: ICH M11 Intervention Use Value Set Terminology


name: ICH M11 Investigational Medicinal Product Indicator Value Set Terminology


name: ICH M11 Trial-Related Safety Event Type Value Set Terminology


name: Medium- to Long-Chain Acylcarnitine Ratio Measurement


name: Anti-CLDN1 Antibody-drug Conjugate ALE.P02


name: Anti-TM4SF1 Antibody-drug Conjugate AGX101


name: Anti-NaPi2b Antibody-drug Conjugate YL205


name: Anti-B7-H3 Antibody-drug Conjugate ILB-3101


name: Anti-PTK7 Antibody-drug Conjugate SKB518


name: Splenic Marginal Zone Lymphoma by Ann Arbor Stage


name: ICH M11 Protocol Section 1 Data Element Terminology


name: ICH M11 Protocol Section 2 Data Element Terminology


name: ICH M11 Protocol Section 3 Data Element Terminology


name: ICH M11 Protocol Section 4 Data Element Terminology


name: ICH M11 Protocol Section 5 Data Element Terminology


name: ICH M11 Protocol Section 6 Data Element Terminology


name: ICH M11 Protocol Section 7 Data Element Terminology


name: ICH M11 Protocol Section 9 Data Element Terminology


name: ICH M11 Protocol Section 10 Data Element Terminology


name: ICH M11 Protocol Section 11 Data Element Terminology


name: ICH M11 Protocol Section 12 Data Element Terminology


name: ICH M11 Protocol Section 13 Data Element Terminology


name: ICH M11 Protocol Section 14 Data Element Terminology


name: ICH M11 Protocol Section Title Page Data Element Terminology


name: ICH M11 Protocol Section Amendment Details Data Element Terminology


name: Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002


name: PQ/CMC Unit Operations Category Terminology


name: PQ/CMC Unit Operations Subcategory Terminology


name: Omentectomy for Reduction of Omental Torsion


name: Vitreous Humor Aspiration with Vitreous Replacement


name: Diagnostic Nuclear Magnetic Resonance Imaging


name: Topical Application of Dental Desensitizing Agent


name: Small Intestinal Excision for Interposition


name: Quantitative Differential Fecal Fat Measurement


name: Transvenous Pulmonary Valve Balloon Commissurotomy


name: Absolute Neutrophil Count Greater than or Equal to 100/mm3


name: St Mark's Fecal Incontinence Overall Score


name: Decimal Korsakovian Series of Attenuation


name: Quintamillesimal Korsakovian Series of Attenuation


name: Millesimal Korsakovian Series of Attenuation


name: Incontinence Impact Questionnaire-Long Form


name: Urinary Incontinence Impact on Doing Household Chores Question


name: Urinary Incontinence Impact on Doing Home Maintenance Work Question


name: Urinary Incontinence Impact on Shopping Activities Question


name: Urinary Incontinence Impact on Hobbies and Pastime Activities Question


name: Urinary Incontinence Impact on Physical Recreation Activities Question


name: Urinary Incontinence Impact on Entertainment Activities Question


name: Urinary Incontinence Impact on Ability to Travel by Car or Bus Close to Home Question


name: Urinary Incontinence Impact on Ability to Travel by Car or Bus Far from Home Question


name: Urinary Incontinence Impact on Going to Places when Not Sure about Restrooms Question


name: Urinary Incontinence Impact on Going on Vacation Question


name: Urinary Incontinence Impact on Attending Church or Temple Question


name: Urinary Incontinence Impact on Doing Volunteer Activities Question


name: Urinary Incontinence Impact on Employment Outside of Home Question


name: Urinary Incontinence Impact on Having Friends Visit at Home Question


name: Urinary Incontinence Impact on Social Activities Outside Home Question


name: Urinary Incontinence Impact on Relationship with Friends Question


name: Urinary Incontinence Impact on Relationship with Family Question


name: Urinary Incontinence Impact on Sexual Relations Question


name: Urinary Incontinence Impact on Way of Dressing Question


name: Urinary Incontinence Impact on Emotional Health Question


name: Urinary Incontinence Impact on Physical Health Question


name: Urinary Incontinence Impact on Sleep Question


name: Fear of Odor Restricts Activities Question


name: Urinary Incontinence Impact on Nervousness or Anxiety Question


name: Urinary Incontinence Impact on Frustration Question


name: Urinary Incontinence Impact on Anger Question


name: Urinary Incontinence Impact on Depression Question


name: Urinary Incontinence Impact on Embarrassment Question


name: Incontinence Impact Questionnaire-Long Form Overall Score


name: Incontinence Impact Questionnaire-Long Form Physical Activity Subscale Score


name: Incontinence Impact Questionnaire-Long Form Travel Subscale Score


name: Incontinence Impact Questionnaire-Long Form Social Subscale Score


name: Incontinence Impact Questionnaire-Long Form Emotional Subscale Score


name: Urine Leakage Related to Physical Activity, Coughing, or Sneezing Question


name: Bothered by Urine Leakage Related to Physical Activity, Coughing, or Sneezing Question


name: Urine Leakage without Urgency or Activity Question


name: Bothered by Leakage of Small Amounts of Urine Question


name: Leakage of Large Amounts of Urine Question


name: Bothered by Leakage of Large Amounts of Urine Question


name: Bothered by Nighttime Urination Question


name: Bothered by Difficulty Emptying Bladder Question


name: Bothered by Feeling of Incomplete Bladder Emptying Question


name: Bothered by Lower Abdomen Pressure Question


name: Bothered by Pain when Urinating Question


name: Bothered by Pain in Lower Abdominal or Genital Area Question


name: Soft Gel Pharmaceutical Formulation Process


name: Heaviness or Dullness in Pelvic Area Question


name: Bothered by Heaviness or Dullness in Pelvic Area Question


name: Feeling of Bulging or Protrusion in Vaginal Area Question


name: Bothered by Feeling of Bulging in Vaginal Area Question


name: Bothered by Visible Bulging in Vaginal Area Question


name: Bothered by Pelvic Discomfort with Standing or Physical Exertion Question


name: Have to Push on Vaginal Wall for Bowel Movement Question


name: Bothered by Having to Push on Vaginal Wall for Bowel Movement Question


name: Symptom that is Most Bothersome Question


name: Urinary Distress Inventory Overall Score


name: Urinary Distress Inventory Obstructive/Discomfort Subscale Score


name: Urinary Distress Inventory Irritative Symptoms Subscale Score


name: Urinary Distress Inventory Stress Symptoms Subscale Score


name: Mixed Normal and Neoplastic Cellular Population


name: Active Pharmaceutical Ingredient Melt Extrusion


name: Direct Heating, Dilute Solids Bed, Spray Drying


name: Indirect Conduction Drying, Moving Solids Bed


name: Indirect Conduction Drying, Static Solids Bed


name: Indirect Radiant Drying, Moving Solids Bed


name: Medical Product Filling or Aseptic Processing


name: Transferring Non-Sterile Medical Product Packaging


name: Testosterone Greater than or Equal to 300 ng/dL


name: Anti-TF/Exatecan Antibody-drug Conjugate ADCE-T02


name: Meter per Square Seconds per Square Root of Hertz


name: Anti-GPRC5D/MMAE Antibody-drug Conjugate AZD0305


name: PEOX-based Polymer Encapsulated SN-38 FID-022


name: SR Mitomycin Intravesical Solution Regimen


name: Accidental Bowel Leakage Evaluation Overall Score


name: Accidental Bowel Leakage Evaluation Liquid Stool Subscale Score


name: Accidental Bowel Leakage Evaluation Solid Stool Subscale Score


name: Accidental Bowel Leakage Evaluation Mucus Stool Subscale Score


name: Accidental Bowel Leakage Evaluation Gas Stool Subscale Score


name: Accidental Bowel Leakage Evaluation Predictability/Awareness Subscale Score


name: Accidental Bowel Leakage Evaluation Control Subscale Score


name: Accidental Bowel Leakage Evaluation Ancillary Bowel Symptoms Subscale Score


name: Radiation-related Genomic Profile of Papillary Thyroid Carcinoma (Chernobyl)


name: VRP-encapsulated saRNA Encoding IL-12 VLPONC-01


name: Immunogenicity Specimen Test Operational Objective


name: Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501


name: Breast Imaging Reporting and Data System Atlas


name: Anti-B7-H3/PD-L1-P1003 Bispecific Antibody-drug Conjugate DB-1419


name: Study Risk and Mitigation Strategy Description


name: Approximate Participant Enrollment At Time of Sponsor Approval


name: Trial-Related Statistical Analysis Method


name: Protocol Previously Amended, Details Presented


name: Protocol Previously Amended See Summary of Changes Before the Table of Contents


name: Regulatory Agency Request to Amend Amendment Reason


name: New Regulatory Guidance Amendment Reason


name: New Safety Information Available Amendment Reason


name: New Data Available (Other Than Safety Data) Amendment Reason


name: Investigator/Site Feedback Amendment Reason


name: Inconsistency and/or Error in the Protocol Amendment Reason


name: Reportable Adverse Event of Special Interest


name: Not Reportable Adverse Event of Special Interest


name: ICH M11 Protocol Section 1 PROTOCOL SUMMARY


name: ICH M11 Protocol Section 1.1 Protocol Synopsis


name: ICH M11 Protocol Section 1.1.1 Primary and Secondary Objectives and Estimands


name: ICH M11 Protocol Section 1.1.2 Overall Design


name: ICH M11 Protocol Section 1.2 Trial Schema


name: ICH M11 Protocol Section 1.3 Schedule of Activities


name: ICH M11 Protocol Section 2.1 Purpose of Trial


name: ICH M11 Protocol Section 2.2 Assessment of Risks and Benefits


name: ICH M11 Protocol Section 2.2.1 Risk Summary and Mitigation Strategy


name: ICH M11 Protocol Section 2.2.2 Benefit Summary


name: ICH M11 Protocol Section 2.2.3 Overall Risk-Benefit Assessment


name: ICH M11 Protocol Section 3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS


name: ICH M11 Protocol Section 3.1 Primary Objective(s) and Associated Estimand(s)


name: ICH M11 Protocol Section 3.1.1 Primary Objective


name: ICH M11 Protocol Section 3.2 Secondary Objective(s) and Associated Estimand(s)


name: ICH M11 Protocol Section 3.2.1 Secondary Objective


name: ICH M11 Protocol Section 3.3 Exploratory Objective(s)


name: ICH M11 Protocol Section 3.3.1 Exploratory Objective


name: ICH M11 Protocol Section 4.1 Description of Trial Design


name: ICH M11 Protocol Section 4.1.1 Stakeholder Input into Design


name: ICH M11 Protocol Section 4.2 Rationale for Trial Design


name: ICH M11 Protocol Section 4.2.1 Rationale for Estimand(s)


name: ICH M11 Protocol Section 4.2.2 Rationale for Intervention Model


name: ICH M11 Protocol Section 4.2.3 Rationale for Control Type


name: ICH M11 Protocol Section 4.2.4 Rationale for Trial Duration


name: ICH M11 Protocol Section 4.2.5 Rationale for Adaptive or Novel Trial Design


name: ICH M11 Protocol Section 4.2.6 Rationale for Interim Analysis


name: ICH M11 Protocol Section 4.2.7 Rationale for Other Trial Design Aspects


name: ICH M11 Protocol Section 4.3 Trial Stopping Rules


name: ICH M11 Protocol Section 4.4 Start of Trial and End of Trial


name: ICH M11 Protocol Section 4.5 Access to Trial Intervention After End of Trial


name: ICH M11 Protocol Section 5 TRIAL POPULATION


name: ICH M11 Protocol Section 5.1 Description of Trial Population and Rationale


name: ICH M11 Protocol Section 5.2 Inclusion Criteria


name: ICH M11 Protocol Section 5.3 Exclusion Criteria


name: ICH M11 Protocol Section 5.4 Contraception


name: ICH M11 Protocol Section 5.4.1 Definitions Related to Childbearing Potential


name: ICH M11 Protocol Section 5.4.2 Contraception Requirements


name: ICH M11 Protocol Section 5.5 Lifestyle Restrictions


name: ICH M11 Protocol Section 5.5.1 Meals and Dietary Restrictions


name: ICH M11 Protocol Section 5.5.2 Caffeine, Alcohol, Tobacco, and Other Restrictions


name: ICH M11 Protocol Section 5.5.3 Physical Activity Restrictions


name: ICH M11 Protocol Section 5.5.4 Other Activity Restrictions


name: ICH M11 Protocol Section 5.6 Screen Failure and Rescreening


name: ICH M11 Protocol Section 6 TRIAL INTERVENTION AND CONCOMITANT THERAPY


name: ICH M11 Protocol Section 6.1 Description of Investigational Trial Intervention


name: ICH M11 Protocol Section 6.2 Rationale for Investigational Trial Intervention Dose and Regimen


name: ICH M11 Protocol Section 6.3 Investigational Trial Intervention Administration


name: ICH M11 Protocol Section 6.4 Investigational Trial Intervention Dose Modification


name: ICH M11 Protocol Section 6.5 Management of Investigational Trial Intervention Overdose


name: ICH M11 Protocol Section 6.6 Preparation, Storage, Handling and Accountability of Investigational Trial Intervention


name: ICH M11 Protocol Section 6.6.1 Preparation of Investigational Trial Intervention


name: ICH M11 Protocol Section 6.6.2 Storage and Handling of Investigational Trial Intervention


name: ICH M11 Protocol Section 6.6.3 Accountability of Investigational Trial Intervention


name: ICH M11 Protocol Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding


name: ICH M11 Protocol Section 6.7.1 Participant Assignment to Investigational Trial Intervention


name: ICH M11 Protocol Section 6.7.2 Randomisation


name: ICH M11 Protocol Section 6.7.3 Measures to Maintain Blinding


name: ICH M11 Protocol Section 6.7.4 Emergency Unblinding at the Site


name: ICH M11 Protocol Section 6.8 Investigational Trial Intervention Adherence


name: ICH M11 Protocol Section 6.9 Description of Noninvestigational Trial Intervention


name: ICH M11 Protocol Section 6.9.1 Background Trial Intervention


name: ICH M11 Protocol Section 6.9.2 Rescue Therapy


name: ICH M11 Protocol Section 6.9.3 Other Noninvestigational Trial Intervention


name: ICH M11 Protocol Section 6.10 Concomitant Therapy


name: ICH M11 Protocol Section 6.10.1 Prohibited Concomitant Therapy


name: ICH M11 Protocol Section 6.10.2 Permitted Concomitant Therapy


name: ICH M11 Protocol Section 7 PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL


name: ICH M11 Protocol Section 7.1 Discontinuation of Trial Intervention for Individual Participants


name: ICH M11 Protocol Section 7.1.1 Permanent Discontinuation of Trial Intervention


name: ICH M11 Protocol Section 7.1.2 Temporary Discontinuation of Trial Intervention


name: ICH M11 Protocol Section 7.1.3 Rechallenge


name: ICH M11 Protocol Section 7.2 Participant Discontinuation or Withdrawal from the Trial


name: ICH M11 Protocol Section 7.3 Management of Loss to Follow-Up


name: ICH M11 Protocol Section 8 TRIAL ASSESSMENTS AND PROCEDURES


name: ICH M11 Protocol Section 8.1 Trial Assessments and Procedures Considerations


name: ICH M11 Protocol Section 8.2 Screening/Baseline Assessments and Procedures


name: ICH M11 Protocol Section 8.3 Efficacy Assessments and Procedures


name: ICH M11 Protocol Section 8.4 Safety Assessments and Procedures


name: ICH M11 Protocol Section 8.4.1 Physical Examination


name: ICH M11 Protocol Section 8.4.2 Vital Signs


name: ICH M11 Protocol Section 8.4.3 Electrocardiograms


name: ICH M11 Protocol Section 8.4.4 Clinical Laboratory Assessments


name: ICH M11 Protocol Section 8.4.5 Pregnancy Testing


name: ICH M11 Protocol Section 8.4.6 Suicidal Ideation and Behaviour Risk Monitoring


name: ICH M11 Protocol Section 8.5 Pharmacokinetics


name: ICH M11 Protocol Section 8.6.1 Genetics and Pharmacogenomics


name: ICH M11 Protocol Section 8.6.2 Pharmacodynamic Biomarkers


name: ICH M11 Protocol Section 8.6.3 Other Biomarkers


name: ICH M11 Protocol Section 8.7 Immunogenicity Assessments


name: ICH M11 Protocol Section 8.8 Medical Resource Utilisation and Health Economics


name: ICH M11 Protocol Section 9 ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION, AND SPECIAL SAFETY SITUATIONS


name: ICH M11 Protocol Section 9.1 Definitions


name: ICH M11 Protocol Section 9.1.1 Definitions of Adverse Events


name: ICH M11 Protocol Section 9.1.2 Definitions of Serious Adverse Events


name: ICH M11 Protocol Section 9.1.3 Definitions of Product Complaints


name: ICH M11 Protocol Section 9.1.3.1 Definition of Medical Device Product Complaints


name: ICH M11 Protocol Section 9.2 Timing and Procedures for Collection and Reporting


name: ICH M11 Protocol Section 9.2.2 Collection Procedures


name: ICH M11 Protocol Section 9.2.3 Reporting


name: ICH M11 Protocol Section 9.2.3.1 Regulatory Reporting Requirements


name: ICH M11 Protocol Section 9.2.4 Adverse Events of Special Interest


name: ICH M11 Protocol Section 9.2.5 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs


name: ICH M11 Protocol Section 9.3 Pregnancy and Postpartum Information


name: ICH M11 Protocol Section 9.3.1 Participants Who Become Pregnant During the Trial


name: ICH M11 Protocol Section 9.3.2 Participants Whose Partners Become Pregnant During the Trial


name: ICH M11 Protocol Section 9.4 Special Safety Situations


name: ICH M11 Protocol Section 10 STATISTICAL CONSIDERATIONS


name: ICH M11 Protocol Section 10.1 General Considerations


name: ICH M11 Protocol Section 10.2 Analysis Sets


name: ICH M11 Protocol Section 10.3 Analyses of Demographics and Other Baseline Variables


name: ICH M11 Protocol Section 10.4 Analyses Associated with the Primary Objective(s)


name: ICH M11 Protocol Section 10.4.1 Primary Objective


name: ICH M11 Protocol Section 10.4.1.1 Statistical Analysis Method


name: ICH M11 Protocol Section 10.4.1.2 Handling of Data in Relation to Primary Estimand(s)


name: ICH M11 Protocol Section 10.4.1.3 Handling of Missing Data in Relation to Primary Estimand(s)


name: ICH M11 Protocol Section 10.4.1.4 Sensitivity Analysis


name: ICH M11 Protocol Section 10.4.1.5 Supplementary Analysis


name: ICH M11 Protocol Section 10.5 Analyses Associated with the Secondary Objective(s)


name: ICH M11 Protocol Section 10.5.1 Secondary Objective


name: ICH M11 Protocol Section 10.5.1.1 Statistical Analysis Method


name: ICH M11 Protocol Section 10.5.1.2 Handling of Data in Relation to Secondary Estimand(s)


name: ICH M11 Protocol Section 10.5.1.3 Handling of Missing Data in Relation to Secondary Estimand(s)


name: ICH M11 Protocol Section 10.5.1.4 Sensitivity Analysis


name: ICH M11 Protocol Section 10.5.1.5 Supplementary Analysis


name: ICH M11 Protocol Section 10.6 Analyses Associated with the Exploratory Objective(s)


name: ICH M11 Protocol Section 10.7 Safety Analyses


name: ICH M11 Protocol Section 10.8 Other Analyses


name: ICH M11 Protocol Section 10.9 Interim Analyses


name: ICH M11 Protocol Section 10.10 Multiplicity Adjustments


name: ICH M11 Protocol Section 10.11 Sample Size Determination


name: ICH M11 Protocol Section 11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS


name: ICH M11 Protocol Section 11.1 Regulatory and Ethical Considerations


name: ICH M11 Protocol Section 11.2 Trial Oversight


name: ICH M11 Protocol Section 11.2.1 Investigator Responsibilities


name: ICH M11 Protocol Section 11.2.2 Sponsor Responsibilities


name: ICH M11 Protocol Section 11.3 Informed Consent Process


name: ICH M11 Protocol Section 11.3.1 Informed Consent for Rescreening


name: ICH M11 Protocol Section 11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research


name: ICH M11 Protocol Section 11.4 Committees


name: ICH M11 Protocol Section 11.5 Insurance and Indemnity


name: ICH M11 Protocol Section 11.6 Risk-Based Quality Management


name: ICH M11 Protocol Section 11.7 Data Governance


name: ICH M11 Protocol Section 11.8 Data Protection


name: ICH M11 Protocol Section 11.9 Source Data


name: ICH M11 Protocol Section 11.10 Protocol Deviations


name: ICH M11 Protocol Section 11.11 Early Site Closure


name: ICH M11 Protocol Section 11.12 Data Dissemination


name: ICH M11 Protocol Section 12 APPENDIX: SUPPORTING DETAILS


name: ICH M11 Protocol Section 12.1 Clinical Laboratory Tests


name: ICH M11 Protocol Section 12.2 Country/Region-Specific Differences


name: ICH M11 Protocol Section 12.3 Prior Protocol Amendment(s)


name: ICH M11 Protocol Section 13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS


name: ICH M11 Protocol Section 14 APPENDIX: REFERENCES


name: Amendment Scope Global Applicability Indicator


name: US FDA Investigational New Drug Application Number


name: US FDA Investigational Device Exemption Application Number


name: Japan Registry for Clinical Trials Number


name: Other Regulatory or Clinical Trial Identifier


name: Protocol Approval Date or Location of Date


name: Designated Medical Expert Contact Information or Location of Contact Information


name: Amendment Impacts Participant's Safety or Rights Indicator


name: Brief Explanation of Substantial Impact on Participant Safety


name: Amendment Impacts Reliability and Robustness of Data Indicator


name: Brief Explanation of Substantial Impact on Study Data


name: Drug/Device Combination Product Indicator


name: Trial Participation Number Target or Maximum Indicator


name: Number of Participants Randomly Assigned to Trial Intervention or Enrolled


name: Planned Duration of Trial Intervention Unit of Time


name: Alternate Description of Planned Duration of Trial Intervention


name: Planned Duration of Trial Participation Unit of Time


name: Alternate Description of Planned Duration of Trial Participation


name: Trial-specific Intervention Risks and Mitigation Strategy Description


name: Trial-specific Procedure Risks and Mitigation Strategy Description


name: Trial-specific Other Risks and Mitigation Strategy Description


name: Overall Risk-Benefit Assessment Description


name: Description of Level and Method of Blinding


name: Rationale for Adaptive or Novel Trial Design


name: Rationale for Other Trial Design Aspects


name: Access to Trial Intervention after End of Trial


name: Description of Trial Population and Rationale


name: Definitions Related to Trial Participant Childbearing Potential


name: Trial Participant Contraception Requirements


name: Trial Participant Lifestyle Restrictions


name: Trial Participant Meals and Dietary Restrictions


name: Trial Participant Caffeine, Alcohol, Tobacco, and Other Substance Restrictions


name: Trial Participant Physical Activity Restrictions


name: Trial Intervention Overview or Informational Table Header


name: Investigational Intervention Sourcing Indicator


name: Description of Investigational Trial Intervention


name: Rationale for Investigational Trial Intervention Dose and Regimen


name: Investigational Trial Intervention Administration


name: Investigational Trial Intervention Dose Modification


name: Management of Investigational Trial Intervention Overdose


name: Participant Assignment to Investigational Intervention Method


name: Investigational Trial Intervention Adherence Measures Description


name: Description of Noninvestigational Trial Intervention


name: Other Noninvestigational Trial Intervention


name: Requirements for Permanent Discontinuation of Trial Intervention


name: Requirements for Temporary Discontinuation of Trial Intervention


name: Trial Assessments and Procedures Considerations Description


name: Screening Assessments and Procedures Description


name: Baseline Assessments and Procedures Description


name: Efficacy Assessments and Procedures Description


name: Safety Assessments and Procedures Description


name: Suicidal Ideation and Behaviour Risk Monitoring


name: Genetics and Pharmacogenomics Assessment


name: Definition of Medical Device Product Complaints


name: Safety Event Situational Scope Description


name: Timing Description for Reporting to Sponsor or Designee


name: Event Collection and Reporting Timing Description


name: Regulatory Reporting Requirements for Trial-Related Events


name: Disease-related Events or Outcomes Not Qualifying as Adverse Events or Serious Adverse Events


name: Participants Who Become Pregnant During the Trial Data Collection


name: Participants Whose Partners Become Pregnant During the Trial Data Collection


name: Description of the Participants Included in Data Analysis


name: Description of Trial Baseline Variable Analysis


name: Handling of Data in Relation to Primary Estimand(s)


name: Handling of Missing Data in Relation to Primary Estimand(s)


name: Handling of Data in Relation to Secondary Estimand(s)


name: Handling of Missing Data in Relation to Secondary Estimand(s)


name: Exploratory Objective Statistical Analysis Method


name: Trial Regulatory and Ethical Consideration


name: Description of Emergency Consent Process


name: Informed Consent Requirements for Rescreening


name: Informed Consent Requirements for Use of Remaining Samples in Exploratory Research


name: Investigator Expectations for Source Data


name: Trial Monitor Expectations for Source Data


name: Responsibilities Following Early Trial Site Closure


name: Country and/or Region-Specific Trial Requirements


name: Country and/or Region-Specific Protocol Clarifications Description


name: Alternative Location of Protocol Changes


name: Primary and Secondary Objectives and Estimands Summary


name: Anti-nectin-4 Antibody-drug Conjugate MK-3120


name: Modified Aldesleukin/Palivizumab Fusion Protein IOV-3001


name: Anti-CD37/DM1 Derivative Antibody-drug Conjugate Debio 1562M


name: STATA Statistical Software for Data Science


name: Speech Disturbance Assessment for Ataxia


name: Fast Alternating Hand Movement Assessment for Ataxia


name: Akkermansia muciniphila/Anaerobutyricum hallii/Bifidobacterium infantis/Clostridium beijerinckii/Clostridium butyricum/Inulin WBF-038


name: Theobromine Sodium Salicylate Monohydrate


name: Inability to Commit to the Clinical Trial


name: Hyaluronic Acid/Sweet Almond Oil Vaginal Suppository


name: Anti-CDH17 Antibody-drug Conjugate YL217


name: Powder for Solution for Inhalation Dosage Form


name: Colloidal Suspension for Injection Dosage Form


name: Metered Powder for Inhalation Dosage Form


name: Lyophilized Powder for Extended Release Injectable Liposomal Suspension Dosage Form


name: Pressurized Nebulizer Suspension Dosage Form


name: Microspheres for Injectable Suspension Dosage Form


name: Breath-activated Powder Inhaler Dosage Form


name: SERPINA1 Homozygous ZZ Genotype Positive


name: Description of Method of Assignment to Trial Intervention


name: Regimen Used to Treat Myeloproliferative Neoplasm


name: Circulating Tumor Tissue Modified Viral HPV DNA Positive


name: Circulating Tumor Tissue Modified Viral HPV DNA Score Less than or Equal to 50


name: Helper-dependent Adenovirus 3/35++ Encoding CYBB Transgene EN-374


name: Progesterone Receptor Positive by Immunohistochemistry Greater than or Equal to 10 Percent


name: CDISC SDTM ECG Analysis Method Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life - Anal Cancer 27 Items Test Name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life - Anal Cancer 27 Items Test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer 21 Items Test Name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Bone Metastases 22 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Bone Metastases 22 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer 42 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer 42 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Chronic Lymphocytic Leukemia 17 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Chronic Lymphocytic Leukemia 17 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Head and Neck Cancer Phase IV Module Version 43 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Head and Neck Cancer Phase IV Module Version 43 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Information 25 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Information 25 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Liver Metastases 21 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Liver Metastases 21 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Multiple Myeloma 20 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Multiple Myeloma 20 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Non-Muscle-Invasive Bladder Cancer 24 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Non-Muscle-Invasive Bladder Cancer 24 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophageal Cancer 18 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophageal Cancer 18 Items test code Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophago-Gastric Cancer Phase IV Module Version 25 Items test name Terminology


name: CDISC Questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophago-Gastric Cancer Phase IV Module Version 25 Items test code Terminology


name: EORTC QLQ-H and N43 Phase IV Module Version Questionnaire Question


name: EORTC QLQ-NMIBC24 Questionnaire Question


name: Findings About Last Observation Before Exposure Flag


name: Circulating Immune Cell Characterization


name: Blood-Brain Barrier Permeability Characterization


name: Multiplex Plasma Biomarker Characterization


name: Antibody to Single and Double Stranded DNA Ratio Measurement


name: Antibody to Single Stranded DNA Ratio Measurement


name: Colony Forming Unit-Granulocyte Erythrocyte Monocyte Megakaryocyte Assay


name: Endoscopic Denker Operation for Radical Maxillary Antrostomy


name: Gas Chromatography/Electron Capture Detection


name: Gas Chromatography/Flame Photometric Detection


name: Magnetic Foreign Body Extraction from the Ciliary Body


name: Neuromuscular Electrical Stimulator Replacement


name: Radical Penectomy with Bilateral Lymphadenectomy


name: Rodney Smith Hepaticojejunostomy with Radical Subtotal Pancreatectomy


name: Sensititre Antimicrobial Susceptibility Testing


name: Staphlococcus aureus Phage Lysate Skin Test


name: Synovial Fluid Cell Count with Differential


name: Terminal Deoxynucleotidyl Transferase Staining Method


name: Urine Coproporphyrin I and Urine Coproporphyrin III Measurement


name: Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284


name: European Quality of Life Five Dimension Five Level Scale Interviewer Administered Questionnaire Version 1.2


name: European Quality of Life Five Dimension Five Level Scale Proxy 1 Questionnaire Version 2.0


name: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 24 Items


name: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 29 Items


name: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer 42 Items


name: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Head and Neck Cancer Phase IV Module Version 43 Items


name: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Version 1.0 23 Items


name: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Head & Neck Cancer Version 1 35 Items


name: MCEQ - Enjoy Respiratory Sensation Score


name: EORTC QLQ-ANL27 - Leakage Stools or Mucus Anal Opening


name: EORTC QLQ-ANL27 - Frequent Bowel Movements


name: EORTC QLQ-ANL27 - Bowel Movements Been Painful


name: EORTC QLQ-ANL27 - Pain or Discomfort Anal Opening


name: EORTC QLQ-ANL27 - Uncomfortable in Certain Positions


name: EORTC QLQ-ANL27 - Soreness in Areas Treated


name: EORTC QLQ-ANL27 - Itchy or Irritated Skin Areas Treated


name: EORTC QLQ-ANL27 - Swelling in Legs or Ankles


name: EORTC QLQ-ANL27 - Problems Going Out Need Toilet


name: EORTC QLQ-ANL27 - Clean Yourself More Often


name: EORTC QLQ-ANL27 - Problems Planning Activities


name: EORTC QLQ-ANL27 - No Stoma: Problems With Gas


name: EORTC QLQ-ANL27 - No Stoma: Move Bowels Hurry Toilet


name: EORTC QLQ-ANL27 - No Stoma: Unable to Empty Bowels


name: EORTC QLQ-ANL27 - Stoma: Sore Skin Around Stoma


name: EORTC QLQ-ANL27 - Stoma: Leakage of Stools Stoma Bag


name: EORTC QLQ-ANL27 - Stoma: Unintentional Gas Stoma Bag


name: EORTC QLQ-ANL27 - Extent Interested in Sex


name: EORTC QLQ-ANL27 - Disease or Treatment Affect Sex Life


name: EORTC QLQ-ANL27 - Pain During Intercourse


name: EORTC QLQ-ANL27 - Men: Difficulty Getting Erection


name: EORTC QLQ-ANL27 - Women: Vagina Felt Dry


name: EORTC QLQ-ANL27 - Women: Vagina Felt Narrow or Tight


name: EORTC QLQ-ANL27 - Women: Vagina Been Painful


name: EORTC QLQ-BIL21 - Problems With Sense of Taste


name: EORTC QLQ-BIL21 - Restricted in Types of Food


name: EORTC QLQ-BIL21 - Skin or Eyes Been Yellow


name: EORTC QLQ-BIL21 - Worried About Skin Being Yellow


name: EORTC QLQ-BIL21 - Less Active Than You Like


name: EORTC QLQ-BIL21 - Felt Lacking in Energy


name: EORTC QLQ-BIL21 - Bloated Feeling in Abdomen


name: EORTC QLQ-BIL21 - Felt Less Able to Enjoy Yourself


name: EORTC QLQ-BIL21 - Worried About Health in Future


name: EORTC QLQ-BIL21 - Worried About Family in Future


name: EORTC QLQ-BIL21 - Extent Troubled With Side-effects


name: EORTC QLQ-BIL21 - Difficulties Drainage Tubes/Bags


name: EORTC QLQ-BIL21 - Worried About Losing Weight


name: EORTC QLQ-BM22 - Pain in Arm or Shoulder


name: EORTC QLQ-BM22 - Pain Not Relieved by Medications


name: EORTC QLQ-BM22 - Pain When Trying to Stand Up


name: EORTC QLQ-BM22 - Pain With Strenuous Activity


name: EORTC QLQ-BM22 - Pain Interfered Sleeping at Night


name: EORTC QLQ-BM22 - Modify Daily Activities


name: EORTC QLQ-BM22 - Isolated From Those Close to You


name: EORTC QLQ-BM22 - Worried About Loss of Mobility


name: EORTC QLQ-BM22 - Worried Becoming Dependent Illness


name: EORTC QLQ-BM22 - Worried About Health in Future


name: EORTC QLQ-BM22 - Hopeful Pain Will Get Better


name: EORTC QLQ-BM22 - Felt Positive About Health


name: EORTC QLQ-BR42 - Food & Drink Taste Different


name: EORTC QLQ-BR42 - Eyes Painful or Irritated or Watery


name: EORTC QLQ-BR42 - Lost Hair: Upset by Loss of Hair


name: EORTC QLQ-BR42 - Felt Physically Less Attractive


name: EORTC QLQ-BR42 - Problems Looking at Yourself Naked


name: EORTC QLQ-BR42 - Worried About Health in Future


name: EORTC QLQ-BR42 - Problem Raising Arm or Moving Sideways


name: EORTC QLQ-BR42 - Pain in Affected Breast


name: EORTC QLQ-BR42 - Affected Breast Swollen


name: EORTC QLQ-BR42 - Affected Breast Oversensitive


name: EORTC QLQ-BR42 - Skin Problems on Affected Breast


name: EORTC QLQ-BR42 - Redness on Hands or Feet


name: EORTC QLQ-BR42 - Tingling in Fingers or Toes


name: EORTC QLQ-BR42 - Numbness in Fingers or Toes


name: EORTC QLQ-BR42 - Aches or Pains in Bones


name: EORTC QLQ-BR42 - Sexual: Pain in Vagina During Sex


name: EORTC QLQ-BR42 - Sexual: Dry Vagina During Sex


name: EORTC QLQ-BR42 - Satisfied With Cosmetic Result


name: EORTC QLQ-BR42 - Satisfied With Appearance of Skin


name: EORTC QLQ-CLL17 - Aches or Pains in Muscles or Joints


name: EORTC QLQ-CLL17 - Aches or Pain in Bones


name: EORTC QLQ-CLL17 - Shortness of Breath on Exertion


name: EORTC QLQ-CLL17 - Worried About Health in Future


name: EORTC QLQ-CLL17 - Worried About Recurrence Disease


name: EORTC QLQ-CLL17 - Worried About Get Another Cancer


name: EORTC QLQ-CLL17 - Worried Treatment Cause Future Problems


name: EORTC QLQ-CLL17 - Problems at Work Due to Disease


name: EORTC QLQ-CLL17 - Worried Not Able Continue Working


name: EORTC QLQ-H and N43 Phase IV Module Version - Pain in Mouth


name: EORTC QLQ-H and N43 Phase IV Module Version - Pain in Jaw


name: EORTC QLQ-H and N43 Phase IV Module Version - Soreness in Mouth


name: EORTC QLQ-H and N43 Phase IV Module Version - Pain in Throat


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Swallowing Liquids


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Swallowing Pureed Food


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Swallowing Solid Food


name: EORTC QLQ-H and N43 Phase IV Module Version - Choked When Swallowing


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems With Teeth


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Because Losing Teeth


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Opening Mouth Wide


name: EORTC QLQ-H and N43 Phase IV Module Version - Dry Mouth


name: EORTC QLQ-H and N43 Phase IV Module Version - Sticky Saliva


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems With Sense of Smell


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems With Sense of Taste


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems With Coughing


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems With Hoarseness


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems With Appearance


name: EORTC QLQ-H and N43 Phase IV Module Version - Felt Less Physically Attractive


name: EORTC QLQ-H and N43 Phase IV Module Version - Dissatisfied With Body


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Eating


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Eating in Front of Family


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Eating in Front of People


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Enjoying Meals


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Talking to Other People


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Talking on Telephone


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Talking Noisy Environment


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Speaking Clearly


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Going Out in Public


name: EORTC QLQ-H and N43 Phase IV Module Version - Less Interest in Sex


name: EORTC QLQ-H and N43 Phase IV Module Version - Less Sexual Enjoyment


name: EORTC QLQ-H and N43 Phase IV Module Version - Prob Raising Arm or Moving Sideways


name: EORTC QLQ-H and N43 Phase IV Module Version - Pain in Shoulder


name: EORTC QLQ-H and N43 Phase IV Module Version - Swelling in Neck


name: EORTC QLQ-H and N43 Phase IV Module Version - Skin Problems


name: EORTC QLQ-H and N43 Phase IV Module Version - Rash


name: EORTC QLQ-H and N43 Phase IV Module Version - Skin Changed Color


name: EORTC QLQ-H and N43 Phase IV Module Version - Worried Weight Too Low


name: EORTC QLQ-H and N43 Phase IV Module Version - Worried About Results Exam & Tests


name: EORTC QLQ-H and N43 Phase IV Module Version - Worried About Health in Future


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems With Wounds Healing


name: EORTC QLQ-H and N43 Phase IV Module Version - Tingling or Numbness in Hands or Feet


name: EORTC QLQ-H and N43 Phase IV Module Version - Problems Chewing


name: EORTC QLQ-INFO25 - Possible Causes of Disease


name: EORTC QLQ-INFO25 - Whether Disease is Under Control


name: EORTC QLQ-INFO25 - Purpose of Medical Tests


name: EORTC QLQ-INFO25 - Procedures of Medical Tests


name: EORTC QLQ-INFO25 - Results of Medical Tests


name: EORTC QLQ-INFO25 - Expected Benefit of Treatment


name: EORTC QLQ-INFO25 - Possible Side-effects of Treatment


name: EORTC QLQ-INFO25 - Effects of Treatment on Symptoms


name: EORTC QLQ-INFO25 - Effects Treatment on Social Life


name: EORTC QLQ-INFO25 - Effects Treatment on Sexual Activity


name: EORTC QLQ-INFO25 - Help Outside Hospital


name: EORTC QLQ-INFO25 - Rehabilitation Services


name: EORTC QLQ-INFO25 - Managing Illness at Home


name: EORTC QLQ-INFO25 - Professional Psychological Support


name: EORTC QLQ-INFO25 - Different Places of Care


name: EORTC QLQ-INFO25 - Things to Help Yourself Get Well


name: EORTC QLQ-INFO25 - Received Written Information


name: EORTC QLQ-INFO25 - Received Information CD or Tape or Video


name: EORTC QLQ-INFO25 - Satisfied Amount of Information


name: EORTC QLQ-INFO25 - Wish to Receive More Information


name: EORTC QLQ-INFO25 - More Information Specify Topics


name: EORTC QLQ-INFO25 - Wish You Received Less Information


name: EORTC QLQ-INFO25 - Less Information Specify Topics


name: EORTC QLQ-INFO25 - Overall Information Helpful


name: EORTC QLQ-LMC21 - Worried About Losing Weight


name: EORTC QLQ-LMC21 - Problems With Sense of Taste


name: EORTC QLQ-LMC21 - Less Active Than You Like


name: EORTC QLQ-LMC21 - Tingling Hands or Feet


name: EORTC QLQ-LMC21 - Discomfort in Stomach Area


name: EORTC QLQ-LMC21 - Skin or Eyes Been Yellow


name: EORTC QLQ-LMC21 - Felt Lacking in Energy


name: EORTC QLQ-LMC21 - Trouble Social Contact Friends


name: EORTC QLQ-LMC21 - Trouble Talking About Feelings


name: EORTC QLQ-LMC21 - Felt Less Able to Enjoy Yourself


name: EORTC QLQ-LMC21 - Worried About Health in Future


name: EORTC QLQ-LMC21 - Worried About Family in Future


name: EORTC QLQ-LMC21 - Disease or Treatment Affect Sex Life


name: EORTC QLQ-MY20 - Pain in Arm or Shoulder


name: EORTC QLQ-MY20 - Pain Increase With Activity


name: EORTC QLQ-MY20 - Lost Hair: Upset by Loss of Hair


name: EORTC QLQ-MY20 - Feel Restless or Agitated


name: EORTC QLQ-MY20 - Acid Indigestion or Heartburn


name: EORTC QLQ-MY20 - Felt Physically Less Attractive


name: EORTC QLQ-MY20 - Worried About Health in Future


name: EORTC QLQ-NMIBC24 - Had to Urinate Frequently During Day


name: EORTC QLQ-NMIBC24 - Urinate Frequently at Night


name: EORTC QLQ-NMIBC24 - Pass Urine Hurry to Get to Toilet


name: EORTC QLQ-NMIBC24 - Difficult Sleep Frequently Urinate


name: EORTC QLQ-NMIBC24 - Difficulty Going Out Need Toilet


name: EORTC QLQ-NMIBC24 - Unintentional Release of Urine


name: EORTC QLQ-NMIBC24 - Pain or Burning When Urinating


name: EORTC QLQ-NMIBC24 - Trouble Arranging Life Appointment


name: EORTC QLQ-NMIBC24 - Worry About Repeated Treatments


name: EORTC QLQ-NMIBC24 - Worried About Health in Future


name: EORTC QLQ-NMIBC24 - Worry About Results Examinations and Tests


name: EORTC QLQ-NMIBC24 - Worry About Future Treatments


name: EORTC QLQ-NMIBC24 - Bloated Feeling in Abdomen


name: EORTC QLQ-NMIBC24 - Extent Interested in Sex


name: EORTC QLQ-NMIBC24 - Extent Sexually Active


name: EORTC QLQ-NMIBC24 - Men: Difficulty Gain or Maintain Erection


name: EORTC QLQ-NMIBC24 - Men: Ejaculation Problems


name: EORTC QLQ-NMIBC24 - Sexual: Uncomfortable Sex Intimate


name: EORTC QLQ-NMIBC24 - Sexual: Worried Contaminate Partner


name: EORTC QLQ-NMIBC24 - Sexual: Extent Sex Enjoyable


name: EORTC QLQ-NMIBC24 - Sexual Women: Dry Vagina Intercourse


name: EORTC QLQ-OES18 - Eat Liquidized or Soft Food


name: EORTC QLQ-OES18 - Trouble Swallowing Saliva


name: EORTC QLQ-OES18 - Choked When Swallowing


name: EORTC QLQ-OES18 - Trouble Enjoying Meals


name: EORTC QLQ-OES18 - Trouble Eating in Front of People


name: EORTC QLQ-OES18 - Food and Drink Taste Different


name: EORTC QLQ-OES18 - Acid Indigestion or Heartburn


name: EORTC QLQ-OES18 - Trouble Acid or Bile Into Mouth


name: EORTC QLQ-OG25 Phase IV Module Version - Problems Eating Solid Foods


name: EORTC QLQ-OG25 Phase IV Module Version - Problems Eat Liquidized or Soft Foods


name: EORTC QLQ-OG25 Phase IV Module Version - Problems Drinking Liquids


name: EORTC QLQ-OG25 Phase IV Module Version - Trouble Enjoying Meals


name: EORTC QLQ-OG25 Phase IV Module Version - Felt Full Too Quickly


name: EORTC QLQ-OG25 Phase IV Module Version - Taken Long Time Complete Meals


name: EORTC QLQ-OG25 Phase IV Module Version - Difficulty Eating


name: EORTC QLQ-OG25 Phase IV Module Version - Acid Indigestion or Heartburn


name: EORTC QLQ-OG25 Phase IV Module Version - Acid or Bile Into Mouth Problem


name: EORTC QLQ-OG25 Phase IV Module Version - Discomfort When Eating


name: EORTC QLQ-OG25 Phase IV Module Version - Pain When Eat


name: EORTC QLQ-OG25 Phase IV Module Version - Pain in Stomach Area


name: EORTC QLQ-OG25 Phase IV Module Version - Discomfort in Stomach Area


name: EORTC QLQ-OG25 Phase IV Module Version - Thinking About Illness


name: EORTC QLQ-OG25 Phase IV Module Version - Worried About Health in Future


name: EORTC QLQ-OG25 Phase IV Module Version - Trouble Eating in Front of People


name: EORTC QLQ-OG25 Phase IV Module Version - Dry Mouth


name: EORTC QLQ-OG25 Phase IV Module Version - Problems With Sense of Taste


name: EORTC QLQ-OG25 Phase IV Module Version - Felt Physically Less Attractive


name: EORTC QLQ-OG25 Phase IV Module Version - Difficulty Swallowing Saliva


name: EORTC QLQ-OG25 Phase IV Module Version - Choked When Swallowing


name: EORTC QLQ-OG25 Phase IV Module Version - Coughed


name: EORTC QLQ-OG25 Phase IV Module Version - Difficulty Talking


name: EORTC QLQ-OG25 Phase IV Module Version - Worried Weight Too Low


name: EORTC QLQ-OG25 Phase IV Module Version - Lost Hair: Upset by Loss of Hair


name: Estrogen Receptor Positive by Immunohistochemistry Greater than or Equal to 50 Percent


name: Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636


name: Blood and Lymphatic System Disorders, CTCAE 6.0


name: Congenital, Familial and Genetic Disorders, CTCAE 6.0


name: General Disorders and Administration Site Conditions, CTCAE 6.0


name: Injury, Poisoning and Procedural Complications, CTCAE 6.0


name: Metabolism and Nutrition Disorders, CTCAE 6.0


name: Musculoskeletal and Connective Tissue Disorders, CTCAE 6.0


name: Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps), CTCAE 6.0


name: Pregnancy, Puerperium and Perinatal Conditions, CTCAE 6.0


name: Reproductive System and Breast Disorders, CTCAE 6.0


name: Respiratory, Thoracic and Mediastinal Disorders, CTCAE 6.0


name: Skin and Subcutaneous Tissue Disorders, CTCAE 6.0


name: Surgical and Medical Procedures, CTCAE 6.0


name: CTCAE Adverse Events Version 6.0 Terminology


name: Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01


name: Autologous Anti-CLL-1 CAR T-cells ARD103


name: Esophageal Varices Hemorrhage, CTCAE 6.0


name: Alkaline Phosphatase Increased, CTCAE 6.0


name: Grade 2 Myocardial Infarction, CTCAE 6.0


name: Grade 3 Myocardial Infarction, CTCAE 6.0


name: Grade 4 Myocardial Infarction, CTCAE 6.0


name: Grade 5 Myocardial Infarction, CTCAE 6.0


name: Grade 2 Esophageal Varices Hemorrhage, CTCAE 6.0


name: Grade 3 Esophageal Varices Hemorrhage, CTCAE 6.0


name: Grade 4 Esophageal Varices Hemorrhage, CTCAE 6.0


name: Grade 5 Esophageal Varices Hemorrhage, CTCAE 6.0


name: Grade 2 Retroperitoneal Hemorrhage, CTCAE 6.0


name: Grade 3 Retroperitoneal Hemorrhage, CTCAE 6.0


name: Grade 4 Retroperitoneal Hemorrhage, CTCAE 6.0


name: Grade 5 Retroperitoneal Hemorrhage, CTCAE 6.0


name: Grade 1 Systemic Post-Immunization Reation, CTCAE


name: Grade 2 Systemic Post-Immunization Reation, CTCAE


name: Grade 3 Systemic Post-Immunization Reation, CTCAE


name: Grade 4 Systemic Post-Immunization Reation, CTCAE


name: Grade 1 Alkaline Phosphatase Increased, CTCAE 6.0


name: Grade 1 Urinary Protein Increased, CTCAE


name: Grade 2 Urinary Protein Increased, CTCAE


name: Grade 3 Urinary Protein Increased, CTCAE


name: Grade 2 Ovarian Function Insufficiency, CTCAE


name: Anti-FGFR3 Antibody-drug Conjugate BHV-1530


name: FDA-NIH Modernizing Research and Evidence Glossary Terminology


name: European LeukemiaNet 2022 Risk Stratification


name: Grade 2 Thrombotic Microangiopathy, CTCAE 6.0


name: Grade 3 Thrombotic Microangiopathy, CTCAE 6.0


name: Grade 4 Thrombotic Microangiopathy, CTCAE 6.0


name: Grade 5 Thrombotic Microangiopathy, CTCAE 6.0


name: Peripheral Blood Mononuclear Cell Recovery


name: Health and Quality of Life Rating Scale Score


name: Distress Score Visual Analogue Scale Score


name: Lack of Appetite Visual Analogue Scale Score


name: Shortness of Breath Visual Analogue Scale Score


name: Other Problem Visual Analogue Scale Score


name: Symptoms Intensity and Distress Likert Scale Score


name: Quality of Life Linear Analogue Scale Score


name: Baseline Nausea and Vomiting Scale Score


name: Physician's Global Assessment Scale of Epidermal Chronic Graft versus Host Disease Score


name: Illness Intrusiveness Ratings Scale Score


name: COVID-19 Disease WHO Severity Scale Score


name: Secondary Hemophagocytic Lymphohistiocytosis, CTCAE


name: Immune Effector Cell-Associated Neurotoxicity Syndrome, CTCAE


name: Tumor Inflammation-Associated Neurotoxicity, CTCAE


name: London Deauville Criteria Point Scale Score


name: Grade 1 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE


name: Grade 1 Tumor Inflammation-Associated Neurotoxicity, CTCAE


name: Grade 1 Tubulointerstitial Nephritis, CTCAE


name: Grade 1 Left Ventricular Dysfunction, CTCAE


name: Grade 1 Immune Effector Cell-Associated Neurotoxicity Syndrome, CTCAE


name: Grade 1 Neutrophil Count Increased, CTCAE


name: Grade 2 Creatinine Clearance Decreased, CTCAE


name: Grade 2 Tubulointerstitial Nephritis, CTCAE


name: Grade 2 Cerebral Venous Sinus Thrombosis, CTCAE


name: Grade 2 Left Ventricular Dysfunction, CTCAE


name: Grade 2 Tumor Inflammation-Associated Neurotoxicity, CTCAE


name: Grade 2 Immune Effector Cell-Associated Neurotoxicity Syndrome, CTCAE


name: Grade 2 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE


name: Grade 2 Graft Versus Host Disease, CTCAE


name: Grade 3 Creatinine Clearance Decreased, CTCAE


name: Grade 3 Graft Versus Host Disease, CTCAE


name: Grade 3 Tubulointerstitial Nephritis, CTCAE


name: Grade 3 Cerebral Venous Sinus Thrombosis, CTCAE


name: Grade 3 Left Ventricular Dysfunction, CTCAE


name: Grade 3 Tumor Inflammation-Associated Neurotoxicity, CTCAE


name: Grade 3 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE


name: Grade 3 Immune Effector Cell-Associated Neurotoxicity Syndrome, CTCAE


name: Grade 4 Graft Versus Host Disease, CTCAE


name: Grade 4 Tubulointerstitial Nephritis, CTCAE


name: Grade 4 Cerebral Venous Sinus Thrombosis, CTCAE


name: Grade 4 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE


name: Grade 4 Immune Effector Cell-Associated Neurotoxicity Syndrome, CTCAE


name: Grade 4 Tumor Inflammation-Associated Neurotoxicity, CTCAE


name: Grade 5 Tubulointerstitial Nephritis, CTCAE


name: Grade 5 Cerebral Venous Sinus Thrombosis, CTCAE


name: Grade 5 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE


name: Grade 5 Immune Effector Cell-Associated Neurotoxicity Syndrome, CTCAE


name: Grade 5 Tumor Inflammation-Associated Neurotoxicity, CTCAE


name: Grade 1 Ovarian Function Insufficiency, CTCAE


name: Grade 1 Chronic Kidney Disease, CTCAE 6.0


name: Grade 2 Chronic Kidney Disease, CTCAE 6.0


name: Grade 3 Chronic Kidney Disease, CTCAE 6.0


name: Grade 4 Chronic Kidney Disease, CTCAE 6.0


name: Grade 5 Chronic Kidney Disease, CTCAE 6.0


name: Grade 1 Spinal Cord Compression, CTCAE 6.0


name: Grade 2 Spinal Cord Compression, CTCAE 6.0


name: Grade 3 Spinal Cord Compression, CTCAE 6.0


name: Grade 4 Spinal Cord Compression, CTCAE 6.0


name: Grade 5 Spinal Cord Compression, CTCAE 6.0


name: Grade 1 Intracranial Hemorrhage, CTCAE 6.0


name: Grade 3 Intracranial Hemorrhage, CTCAE 6.0


name: Grade 4 Intracranial Hemorrhage, CTCAE 6.0


name: Grade 5 Intracranial Hemorrhage, CTCAE 6.0


name: Grade 1 Neutrophil Count Decreased, CTCAE 6.0


name: Grade 2 Neutrophil Count Decreased, CTCAE 6.0


name: Grade 3 Neutrophil Count Decreased, CTCAE 6.0


name: Grade 4 Neutrophil Count Decreased, CTCAE 6.0


name: Pembrolizumab Followed by Cisplatin/Pembrolizumab Followed by Pembrolizumab Regimen


name: Grade 1 Blood Bilirubin Increased, CTCAE 6.0


name: Grade 2 Blood Bilirubin Increased, CTCAE 6.0


name: Grade 3 Blood Bilirubin Increased, CTCAE 6.0


name: Grade 4 Blood Bilirubin Increased, CTCAE 6.0


name: Grade 1 Blood Gonadotrophin Abnormal, CTCAE 6.0


name: Grade 2 Blood Gonadotrophin Abnormal, CTCAE 6.0


name: Forced Expiratory Volume Decreased, CTCAE 6.0


name: Grade 1 Forced Expiratory Volume Decreased, CTCAE 6.0


name: Grade 2 Forced Expiratory Volume Decreased, CTCAE 6.0


name: Grade 3 Forced Expiratory Volume Decreased, CTCAE 6.0


name: AFP Decrease Greater than or Equal to 20 Percent


name: Healthcare System Continuity of Coverage


name: Individually Randomized Group Treatment Trial


name: PD-L1 Combined Positive Score Less than 1


name: EGFR Exon 20 Insertion Mutation Negative


name: Conventional Effector Memory T-Lymphocyte Count


name: Transitional 2 B-Lymphocyte to B-Lymphocyte Ratio Measurement


name: Type 1 Myeloid Dendritic Cell to Dendritic Cell Ratio Measurement


name: Type 2 Myeloid Dendritic Cell to Dendritic Cell Ratio Measurement


name: Conventional Central Memory T-Lymphocyte Count


name: Conventional Effector Memory T-Lymphocyte to T-Lymphocyte Ratio Measurement


name: Conventional T-Lymphocyte Subpopulation Count


name: Conventional Stem Cell Memory T-Lymphocyte Count


name: Conventional Terminal Memory T-Lymphocyte Count


name: Regulatory Memory B-Lymphocyte to Regulatory B-Lymphocyte Ratio Measurement


name: Regulatory Memory B-Lymphocyte Subpopulation Count


name: Conventional Central Memory T-Lymphocyte to T-Lymphocyte Ratio Measurement


name: Conventional Naive T-Lymphocyte Subpopulation Count


name: Conventional Naive T-Lymphocyte to T-Lymphocyte Ratio Measurement


name: Conventional Stem Cell Memory T-Lymphocyte Subpopulation Count


name: Conventional Stem Cell Memory T-Lymphocyte to T-Lymphocyte Ratio Measurement


name: Conventional T-Lymphocyte Subpopulation to T-Lymphocyte Ratio Measurement


name: Conventional Terminal Memory T-Lymphocyte Subpopulation Count


name: Conventional Terminal Memory T-Lymphocyte to T-Lymphocyte Ratio Measurement


name: Double-Negative T-Lymphocyte to Lymphocyte Ratio Measurement


name: Double-Negative T-Lymphocyte Subpopulation Count


name: Double-Positive T-Lymphocyte Subpopulation Count


name: Regulatory Memory B-Lymphocyte Subpopulation to Regulatory B-Lymphocyte Ratio Measurement


name: Risk Evaluation and Mitigation Strategy Program


name: Conventional Stem Cell Memory T-Lymphocyte to Conventional T-Lymphocyte Ratio Measurement


name: Th17-like Helper Regulatory Effector T-Lymphocyte to Helper Regulatory T-Lymphocyte Ratio Measurement


name: Lineage Negative Lymphocyte and Monocyte Subpopulation Count


name: Antibody-Secreting B-Lymphocyte to Class-Switched Memory B-Lymphocyte Ratio Measurement


name: Basophil Subpopulation to Basophil Ratio Measurement


name: Regulatory Memory B-Lymphocyte to B-Lymphocyte Ratio Measurement


name: Regulatory Memory B-Lymphocyte Subpopulation to B-Lymphocyte Ratio Measurement


name: Regulatory Memory B-Lymphocyte Subpopulation to Regulatory Memory B-Lymphocyte Ratio Measurement


name: B-Lymphocyte to Lymphocyte and Monocyte Ratio Measurement


name: Transitional 2 B-Lymphocyte Subpopulation to B-Lymphocyte Ratio Measurement


name: Transitional 2 B-Lymphocyte Subpopulation to Transitional 2 B-Lymphocyte Ratio Measurement


name: Non-class-switched Memory B-Lymphocyte Subpopulation to B-Lymphocyte Ratio Measurement


name: Memory B-Lymphocyte Subpopulation to B-Lymphocyte Ratio Measurement


name: Naive B-Lymphocyte Subpopulation to B-Lymphocyte Ratio Measurement


name: Type 1 Myeloid Dendritic Cell Subpopulation to Dendritic Cell Ratio Measurement


name: Type 2 Myeloid Dendritic Cell Subpopulation to Dendritic Cell Ratio Measurement


name: Lymphocyte and Monocyte to Leukocyte Ratio Measurement


name: Lineage Negative Lymphocyte and Monocyte Count


name: Lymphocyte and Monocyte Subpopulation Count


name: Conventional Central Memory T-Lymphocyte Subpopulation Count


name: Conventional Central Memory T-Lymphocyte to Conventional T-Lymphocyte Ratio Measurement


name: Conventional Central Memory T-Lymphocyte to Helper T-Lymphocyte Ratio Measurement


name: Conventional Central Memory T-Lymphocyte Subpopulation to Conventional Central Memory T-Lymphocyte Ratio Measurement


name: Conventional Effector Memory T-Lymphocyte Subpopulation Count


name: Conventional Effector Memory T-Lymphocyte Subpopulation to Conventional Effector Memory T-Lymphocyte Ratio Measurement


name: Conventional Effector Memory T-Lymphocyte to Conventional T-Lymphocyte Ratio Measurement


name: Conventional Effector Memory T-Lymphocyte to Helper T-Lymphocyte Ratio Measurement


name: Conventional T-Lymphocyte to Leukocyte Ratio Measurement


name: Conventional Naive T-Lymphocyte Subpopulation to Conventional Naive T-Lymphocyte Ratio Measurement


name: Conventional Naive T-Lymphocyte to Conventional T-Lymphocyte Ratio Measurement


name: Conventional Naive T-Lymphocyte to Helper T-Lymphocyte Ratio Measurement


name: Conventional Stem Cell Memory T-Lymphocyte Subpopulation to Conventional Stem Cell Memory T-Lymphocyte Ratio Measurement


name: Conventional Stem Cell Memory T-Lymphocyte to Helper T-Lymphocyte Ratio Measurement


name: Conventional T-Lymphocyte Subpopulation to Conventional T-Lymphocyte Ratio Measurement


name: Conventional T-Lymphocyte Subpopulation to Helper T-Lymphocyte Ratio Measurement